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Background: A recent genome-wide association study (GWAS) identified 99 loci that contain genetic 
risk variants shared between asthma, hay fever and eczema. Many more risk loci shared between these 
common allergic diseases remain to be discovered, which could point to new therapeutic opportunities. 
Objective: To identify novel risk loci shared between asthma, hay fever and eczema by applying a 
gene-based test of association to results from a published GWAS that included data from 360,838 
individuals. 
Methods: We used approximate conditional analysis to adjust the results from the published GWAS for 
the effects of the top risk variants identified in that study. We then analysed the adjusted GWAS results 
with the EUGENE gene-based approach, which combines evidence for association with disease risk 
across regulatory variants identified in different tissues. Novel gene-based associations were followed 
up in an independent sample of 233,898 individuals from the UK Biobank study. 
Results: Of the 19,432 genes tested, 30 had a significant gene-based association at a Bonferroni-
corrected P-value of 2.5x10-6. Of these, 20 were also significantly associated (P<0.05/30=0.0016) with 
disease risk in the replication sample, including 19 that were located in 11 loci not reported to contain 
allergy risk variants in previous GWAS. Amongst these were nine genes with a known function that is 
directly relevant to allergic disease: FOSL2, VPRBP, IPCEF1, PRR5L, NCF4, APOBR, IL27, ATXN2L 
and LAT. For four genes (e.g. ATXN2L), a genetically-determined decrease in gene expression was 
associated with decreased allergy risk, and therefore drugs that inhibit gene expression or function are 
predicted to ameliorate disease symptoms. The opposite directional effect was observed for 14 genes, 
including IL27, a cytokine known to suppress Th2 responses. 
Conclusion: Using a gene-based approach, we identified 11 risk loci for allergic disease that were not 
reported in previous GWAS. Functional studies that investigate the contribution of the 19 associated 
















The strong genetic correlations between asthma, hay fever and eczema estimated from twin studies1-5, 
in combination with the highly polygenic architecture of these diseases, predict that many hundreds if 
not thousands of genetic risk factors are shared between these three common allergic diseases. 
Motivated by this prediction, we recently performed a genome-wide association study (GWAS) 
designed to identify genetic risk variants that are shared between asthma, hay fever and eczema 6. In 
that GWAS, cases (n=180,129) were defined as individuals who reported having suffered from one or 
more allergic disease, while controls (n=180,709) were individuals who reported never having suffered 
from any of these diseases. We identified 136 single nucleotide polymorphisms (SNPs) located in 99 
loci (i.e. genomic regions located > 1Mb apart) that were independently associated with disease risk at 
a genome-wide significance-threshold of P<3x10-8, a threshold that corrects for the number of SNPs 
tested 7. In our study, we often observed that multiple independent genetic variants within one locus 
contributed to disease risk – this was the case for 18 of the 99 risk loci identified.  
Larger GWAS of this multi-disease phenotype are underway and are expected to identify more 
risk variants shared between asthma, hay fever and eczema. Here, we report results from another 
approach that increases power to identify novel risk loci: gene-based instead of SNP-based association 
analysis. Different gene-based tests have been developed, including VEGAS 8, MAGMA 9 and fastBAT 
10
. For each gene in the genome, these methods combine in a single test the evidence for association 
with a disease across multiple SNPs, which are typically selected because they are located in or near 
that gene (e.g. within 100 kb). These methods improve power over the alternative approach of testing 
each SNP at a time (as is done in a GWAS) when multiple SNPs near a gene are independently 
associated with disease risk. However, not all SNPs near a gene are directly relevant to its function. For 
example, only some SNPs influence variation in gene expression levels – these are commonly referred 















being associated with common diseases and traits 11. Motivated by these observations, an additional 
suite of gene-based methods has been developed recently that only include in the association test 
functional SNPs, such as eQTL. These include, for example, PrediXcan 12, EUGENE 13 and S-
PrediXcan 14. We developed EUGENE because it was not possible with other methods to combine in 
the same association test information from eQTL identified in different tissues. This feature is 
important because multiple tissue types play a role in allergic disease pathophysiology and tissue-
specific eQTL are common 15. Furthermore, EUGENE also considers regulatory variants with different 
mechanisms of action, for example, variants that affect splicing but not overall transcription levels. 
This increased resolution is expected to increase our ability to identify genes that are causally-related to 
common diseases 16.  
The aims of the present study were to (1) identify novel risk loci shared between asthma, hay 
fever and eczema by applying EUGENE to results from our previous GWAS 6; and (2) follow up the 



















Adjusting GWAS results for the effects of genome-wide significant SNPs 
The starting point for this study was a GWAS of allergic disease reported recently by Ferreira et al. 6, 
which included 360,838 individuals from 13 studies: UK Biobank, 23andMe, GERA, CATSS, NTR, 
LifeLines, TWINGENE, ALSPAC, SALTY, GENEVA, AAGC, GENUFAD-SHIP-1 and GENUFAD-
SHIP-2 (demographics in Table E1 in this article's Online Repository). In that study, single-SNP 
results were corrected for an inflation factor that reflected technical biases and/or population 
stratification (specifically, an LD-score regression intercept18 of 1.04). After that correction, there were 
136 variants independently associated with allergic disease in Ferreira et al. 6. Because our aim was to 
identify new allergy risk loci, we first applied approximate conditional analyses as implemented in the 
GCTA tool 19 to the summary statistics of Ferreira et al. 6 to adjust the single-SNP results for the effects 
of the 136 risk variants (a detailed justification for performing conditional analysis prior to the gene-
based analysis is provided in the Online Repository). In the conditional analysis, linkage disequilibrium 
(LD) between SNPs was estimated using genotype data from 5,000 individuals from the UK Biobank 
study17.  
 
Gene-based analysis of the adjusted GWAS results 
To identify novel risk loci shared between asthma, hay fever and eczema, we analysed the adjusted 
GWAS results with EUGENE13, a gene-based approach that is applicable to summary statistics (i.e. it 
does not require individual-level genetic data for subjects included in the GWAS) and combines 
evidence for association with disease risk across eQTL identified in different tissues. The latter feature 
is important because multiple tissue types play a role in allergic disease pathophysiology and tissue-















 We identified eQTL based on information from 39 published eQTL studies conducted in 19 
tissues or cell types relevant to allergic disease (Table E2 in this article's Online Repository). For each 
eQTL study, we (i) downloaded the original publication tables containing results for the eQTL 
reported; (ii) extracted the SNP identifier, gene name, association P-value and directional effect (if 
available; beta/z-score and effect allele) for all reported eQTL; and (iii) excluded eQTL located >1 Mb 
of the respective gene (i.e. trans eQTL) and/or with an association P>2.3x10-9, a conservative threshold 
that corrects for 21,742 genes in the genome, each tested for association with 1,000 SNPs (as suggested 
by others 20-22). We did not include trans eQTLs in the analysis because often these are thought to 
involve indirect effects 23, for example, where a SNP influences the expression of a gene in cis, which 
in turn affects the expression of many other genes in trans.  
 Having identified a list of cis eQTL for a given gene from published studies, we then reduced 
that list to a set of eQTL in low LD with each other (specifically, with an r2<0.1) using the --clump 
procedure in PLINK v1.90 24. For a given gene, we refer to these as “independent eQTL”, although we 
recognise that some pairs of eQTL will not be in linkage equilibrium. LD was estimated based on 
genetic data from individuals of European descent from the 1000 Genomes Project 23 (n=294, release 
20130502_v5a). Clumping was not performed separately for each tissue or study, but rather applied to 
the overall list of eQTL obtained after considering information from all tissues/studies. If an eQTL was 
identified in multiple tissues/studies, the clumping procedure was performed using the smallest P-value 
reported for that eQTL across all tissues/studies. A file (ASTHMA.20170517.eqtl.proxies.list) 
containing the independent eQTL identified per gene is available at 
https://genepi.qimr.edu.au/staff/manuelF/eugene/main.html. 
For each gene, EUGENE extracts single-SNP association results for each independent eQTL 
(or, if not available, for a proxy with r2>0.8) from the GWAS summary statistics, sums the association 















using Satterthwaite's approximation, which accounts for the LD between eQTL. This approximation 
was originally implemented by Bakshi et al. 10 in the GCTA-fastBAT module and is now also available 
in EUGENE. LD between eQTL was estimated based on data from 294 Europeans from the 1000 
Genomes Project (release 20130502_v5a). The significance threshold required to achieve experiment-
wide significance was set at P < 0.05 / N genes tested. 
 
Replication of significant gene-based associations in an independent sample 
To confirm novel gene-based associations, we analysed an independent sample of unrelated individuals 
of European descent from the UK Biobank study 17. The approach used to select individuals for 
analysis was very similar to that described in detail previously 6. Briefly, we (1) downloaded array 
(805,426 variants) and imputed (92,693,895 variants) genetic data for the entire UK Biobank study, 
comprising 488,377 individuals, in June 2017; (2) pruned the array data down to a set of 29,446 
independent SNPs that had comparable (P>0.005) allele frequencies between Europeans of the 1000 
Genomes Project (CEU, FIN, GBR and TSI groups) and the UK Biobank individuals of European 
descent included in the Ferreira et al. GWAS 6; (3) merged the pruned dataset with data from 1,092 
individuals of known ancestry from the 1000 Genomes Project (release 20130502_v5a); (4) performed 
multi-dimensional scaling (MDS) analysis of identity-by-state allele sharing separately for each of 32 
groups of ~16,000 individuals (to be computationally feasible), including those from the 1000 
Genomes Project; (5) identified and removed individuals who did not cluster closely (within 5 standard 
deviations of MDS components 1 and 2) to individuals of European ancestry from the 1000 Genomes 
Project, resulting in 461,885 individuals; (6) identified and removed any individuals included in, or 
related to (i.e. with a kinship coefficient that indicates 3rd degree relatedness or closer; based on file 
ukb1007_rel_s488374.dat), the 138,354 individuals of the UK Biobank study included in Ferreira et al. 
6















outliers for SNP missingness or genome-wide heterozygosity levels, and/or (iii) with >10 third-degree 
relatives, resulting in 244,395 individuals.  
For each individual, allergic disease status was defined as previously described for the UK 
Biobank study in detail 6. To classify asthma status, we combined information from three sources: (1) 
touchscreen questionnaire (data-field 6152); (2) Non-cancer illness code, self-reported during verbal 
interview (data-field 20002); (3) main (data-field 41202) and secondary (data-field 41204) ICD10 
diagnoses. Specifically, inclusion criteria for cases were: (i) a report of “Asthma” in field 6152 and a 
code for asthma (1111) in field 20002; or (ii) an ICD10 code for asthma in fields 41202 or 41204. 
Exclusion criteria for cases were: (i) a report of COPD in fields 6152 or 20002; or (ii) other self-
reported respiratory diseases in field 20002. Inclusion criteria for controls were no report of asthma in 
fields 6152, 20002, 41202 and 41204. Exclusion criteria for controls were the same as for cases (no 
COPD or other self-reported respiratory diseases). To classify hay fever status, we used the same three 
sources of information. Specifically, inclusion criteria for cases were: (i) a report of “Hay fever, allergic 
rhinitis or eczema” in field 6152 and a code for hay fever (1387) in field 20002; or (ii) an ICD10 code 
for hay fever in fields 41202 or 41204. Inclusion criteria for controls were no report of hay fever in 
fields 6152, 20002, 41202 and 41204. The eczema phenotype was created very similarly to the hay 
fever phenotype. Inclusion criteria for cases were: (i) a report of “Hay fever, allergic rhinitis or 
eczema” in field 6152 and a code for eczema (1452) in field 20002; or (ii) an ICD10 code for eczema 
in fields 41202 or 41204. Inclusion criteria for controls were no report of eczema in fields 6152, 20002, 
41202 and 41204. To create the overall allergic disease phenotype used for analysis, cases were 
individuals classified as suffering from at least one condition (asthma and/or hay fever and/or eczema), 
as described above. Controls were individuals classified as not having suffered from all three 
conditions. Using this approach, the 244,395 individuals selected for analysis (see above) included 
















 SNPTEST was then used to test the association between disease status and imputed genotype 
data for eQTL of genes selected for replication; age, sex and SNP chip were included as covariates. We 
only analysed SNPs imputed based on the Haplotype Reference Consortium panel, given that variants 
imputed from the UK10K + 1000 Genomes panel were not mapped correctly. We also tested the 
association with 1.2 million HapMap3 SNPs in order to estimate the degree of inflation in test statistics 
arising because of unaccounted technical biases, using the LD Score approach25. We observed an LD 
Score intercept of 1.09, which was used to adjust the association results for the eQTL tested. Lastly, 
EUGENE was used as described above to perform the gene-based analysis for all genes selected for 
replication. 
 
Association analyses contrasting individuals suffering from a single allergic disease 
The case-control phenotype analysed in our GWAS6 combined information from asthma, hay fever and 
eczema, and so was expected to improve power to identify risk variants shared between, but not 
specific to any of, the three diseases 26. To understand if gene-based associations discovered through 
the analysis of that multiple-disease phenotype were indeed likely to represent risk factors shared 
across allergic diseases, we performed case-only association analyses as described in detail previously 
6
. First, we tested the association between eQTL of selected genes with three phenotypes that contrasted 
three non-overlapping groups of adults who suffered from a single allergic disease: asthma only cases 
(g1; n=12,268) vs. hay fever only cases (g2; n=33,305); asthma only cases (g1) vs. eczema only cases 
(g3; n=6,276); and hay fever only cases (g2) vs. eczema only cases (g3). For a given eQTL, results 
from these analyses indicate if the risk allele is more (odds ratio [OR] >1) or less (OR<1) common in 
e.g. group 1 (g1) when compared to group 2 (g2). For example, if an eQTL contributed similarly to the 















hay fever only comparison, but an OR>1 in the asthma vs. eczema and hay fever vs. eczema analyses. 
Second, for each gene and phenotype tested, we combined the association results across eQTL using 
EUGENE as we did in the analysis of the adjusted GWAS results described above.  
 


















Identification of novel risk loci for allergic disease through gene-based association analysis 
An overview of the analytical approach used is shown in Figure 1. To identify novel risk loci shared 
between asthma, hay fever and eczema, we first adjusted the association results from Ferreira et al. 6 for 
the 136 genome-wide significant SNPs (i.e. with P<3x10-8) identified in that study using approximate 
conditional analysis (Figure 2A). In the resulting adjusted GWAS, as expected there were no SNPs 
associated with disease risk at P<3x10-8 and located >1Mb from the loci reported in Ferreira et al. 6. On 
the other hand, four SNPs located in loci reported in that study (in/near CADM3, SLC39A8, LRRC43 
and KLF5) were genome-wide significant in the conditional but not in the original analyses, consistent 
with the presence of additional secondary association signals at those established risk loci (Figure 2B). 
Importantly, there was an enrichment in significant SNP associations in the adjusted GWAS (Figure E1 
in the Online Repository), suggesting that many of these associations are likely to represent true-
positive findings. 
 To identify loci that were likely to contain true-positive associations, we applied the EUGENE 
gene-based approach 13 to the adjusted GWAS results. Specifically, we tested the association between 
disease risk and 19,432 genes (or other types of transcripts, such as long non-coding RNAs [lncRNA]) 
that were reported to have one or more independent eQTL in 19 tissues or cell types relevant to allergic 
disease (Table E2 in this article's Online Repository), including whole blood, lung, skin and 
individual immune cell types.  
We identified 30 significant gene-based associations at a Bonferroni-corrected P-value of 
2.5x10-6, which were located in 18 loci (Table 1). The specific eQTL included in the gene-based test 
for each of these 30 genes are listed in Table E3 in this article's Online Repository. For 21 genes, the 
association P-value obtained with the gene-based test was more significant than the P-value obtained 















for the same gene were associated with disease risk (range 2 to 7 associated eQTL per gene; Table 1). 
For eight genes, the difference in significance between the most associated individual eQTL and the 
gene-based test exceeded one order of magnitude (Figure 3). The most extreme example of this was 
the SPNS1 gene on chromosome 16p11.2 (gene-based P=3.5x10-9 versus best individual eQTL 
P=4.8x10-6), for which 6 of the 15 eQTL tested (identified in five tissues) were nominally associated 
with disease risk (Table E4 in this article's Online Repository).  
 
Replication of significant gene-based associations in an independent sample 
Next, we performed a replication study to determine which of the 30 significant gene-based 
associations were likely to represent true-positive findings. To this end, we first identified 71,807 cases 
and 162,091 controls genotyped by the UK Biobank study17 who were unrelated to individuals from 
our initial GWAS 6. We then used EUGENE to test the association in this independent sample between 
case-control status and each of the 30 genes identified above.  
There were 20 significant gene-based associations at a conservative significance threshold that 
accounts for the 30 genes tested (P<0.05/30=0.0016; Table 1). These included 19 genes located in 11 
loci not implicated in allergic disease in previous GWAS: OR10J5 (chromosome 1q23.2); RP11-
534L20.5 (1q32.1); FOSL2 (2p23.2); RBM15B and VPRBP (3p21.2); IPCEF1 (6q25.2); AC004893.11 
(7q22.1); PRR5L (11p13); NSMCE1 (16p12.1); SPNS1 and seven other nearby genes (16p11.2); 
PVALB and NCF4 (22q12.3). Of note, nine of these genes have a known function that is directly 
relevant to the pathophysiology of allergic disease (Table 2).  
 
Predicted directional effect of gene expression on disease risk 
Because the gene-based approach used focuses exclusively on eQTL, which in turn are associated with 















well as the likely gene(s) underlying each association. Furthermore, often (but not always) the 
directional effect of an eQTL on gene expression can be obtained from published eQTL studies. Based 
on this information, for each gene, we determined if the allergy-protective allele of eQTL included in 
the gene-based test was associated with increased or decreased gene expression. This is important 
because drugs that mimic the directional effect of the allergy-protective allele on gene expression might 
be expected to attenuate (rather than exacerbate) allergic disease symptoms.  
When we performed this analysis for the 20 genes with a significant (P<0.0016) association in 
the replication study, we found that for 14 genes the allergy protective allele was associated with 
increased gene expression (Table E5 in this article's Online Repository). This includes, for example, 
the long non-coding RNA RP11-534L20.5, for which information from six different tissues (including 
blood, lung and skin) indicates that increased gene expression has a protective effect on disease risk. 
On the other hand, for four genes (AC004893.11, ATXN2L, NSMCE1, RP11-24N18.1) the allergy 
protective allele was associated with decreased gene expression, while for two genes eQTL directional 
effects were conflicting between studies (IPCEF1, SULT1A1).  
 
Association analyses contrasting individuals suffering from a single allergic disease 
The multiple-disease case-control phenotype analysed in our GWAS6 maximizes power to identify risk 
variants that are shared between asthma, hay fever and eczema26. As such, we expected the 11 novel 
risk loci identified above to have comparable effects on the three individual diseases. To address this 
possibility, we tested the association between the 20 genes in those 11 loci and three phenotypes that 
compared three non-overlapping groups of adults who suffered from a single allergic disease: (1) 
asthma only cases (n=12,268) versus hay fever only cases (n=33,305); (2) asthma only cases versus 
eczema only cases (n=6,276); and (3) hay fever only cases versus eczema only cases. After correcting 















significant association in the asthma versus hay fever, asthma versus eczema or hay fever versus 
eczema analyses (Table E6). Even at a nominal P<0.05, which does not correct for multiple testing, 
only three genes (in two loci) had a significant association in these analyses: OR10J5, RP11-264B17.4 
and LAT. These results indicate that most (if not all) of the 11 novel risk loci identified in this study do 

















By analyzing results from our previous GWAS 6 with a gene-based test of association, followed by 
replication of top findings in an independent sample, we identified 11 loci that contain previously 
unrecognized genetic risk variants for allergic disease. Results from case-only association analyses 
indicate that these loci have similar effects on asthma, hay fever and eczema risk. 
The 11 novel risk loci were not reported in the original GWAS because they did not contain any 
single SNP associated with disease risk at a significance threshold that accounted for the number of 
SNPs tested. We were able to identify these loci in the present study for two main reasons. First, by 
testing individual genes rather than SNPs, the multiple testing burden was greatly reduced; this 
translated into a less stringent threshold required to declare genome-wide significance (P-value of 
2.5x10-6 instead of 3x10-8), which increases power. Second, most of these loci (7 out of 11) contain 
genes for which multiple independent eQTL were individually associated with disease risk. Under this 
scenario, the gene-based test used improves power over the alternative approach of testing individual 
eQTL separately. Overall, our results support the use of gene-based eQTL-centric approaches to 
identify novel risk loci for human diseases and traits, as reported by others 10, 27. 
 Our results point to 19 genes as being the likely candidates underlying the association between 
the 11 new loci and allergic disease risk. We stress, however, that functional studies are now required to 
confirm that the expression of these genes (1) is determined by (not simply associated with) the eQTL 
included in the respective gene-based test; and (2) influences disease pathophysiology. In other words, 
for given locus, we cannot exclude the possibility that a gene with a significant association is not 
causally-related to disease pathophysiology. Instead, for example, it might simply share eQTL with a 
nearby causal gene that was not identified in our analysis. We highlight one possible example of this. 
We observed a genome-wide significant association with a single gene in the 1q23.2 locus: the 















and so could plausibly contribute to the pathophysiology of allergic disease. However, there were four 
additional genes within 1 Mb of OR10J5 that had a statistically (albeit not genome-wide) significant 
gene-based association in our discovery analysis: FCER1A (P=1.2x10-5), DARC (P=0.0005), IFI16 
(P=0.009) and PYHIN1 (P=0.03), the latter reported previously to contain asthma risk variants in 
populations of African ancestry 29. The association with the first two replicated in the independent UKB 
sample: P=4.8x10-7 and P=0.0001, respectively. Therefore, it is possible that FCER1A and/or DARC 
represent causal gene(s) underlying the observed association at this locus. Both are biologically 
plausible candidate allergy risk genes, encoding respectively the alpha subunit of the high-affinity IgE 
receptor and an atypical chemokine receptor 30. Why did our analysis identify OR10J5 and not, for 
example, FCER1A? The gene-based test for OR10J5 included three eQTL (see Table E2 in this article's 
Online Repository), all individually associated (P<0.05) with disease risk; the strongest disease 
association was observed for eQTL rs2427838 (single-SNP P=1.0x10-5). On the other hand, the gene-
based test for FCER1A included these same three eQTL (i.e. these eQTL were shared between OR10J5 
and FCER1A) plus an additional six independent eQTL, none of which were individually associated 
with disease risk. Because the additional eQTL tested for FCER1A were not associated with disease 
risk, the resulting gene-based association was weaker when compared to OR10J5. An interesting 
question is why some but not all eQTL of FCER1A (and other genes) are associated with disease risk; it 
could be, for example, that disease associations are restricted to eQTL that influence gene expression in 
a specific subset of immune cells, or to eQTL that influence multiple relevant genes. Future studies that 
address this question are warranted. 
With the caveat in mind that significant gene-based associations pinpoint causal risk loci but not 
necessarily the right causal gene(s), we note that nine of the 19 genes located in novel risk loci encode 
proteins with a known function that is directly relevant to allergic disease (Table 2). For example, 















complex role in Th17 differentiation and function 33: on the one hand, it represses Th17 signature genes 
(e.g. IL17A), but on the other hand, it promotes the expression of genes that drive Th17 maintenance 
and survival (e.g. IL6R) 33. When we compared the directional effect of FOSL2 eQTL between disease 
risk and gene expression, we found that the allele associated with reduced disease risk was associated 
with increased gene expression. These genetic findings suggest that increased FOSL2 expression 
results in attenuated allergic inflammatory responses. Consistent with this possibility, deletion of a 
FOSL2 repressor in mice decreased the capacity of CD4+ T cells to develop into the pro-inflammatory 
T follicular helper cell lineage following immunization with ovalbumin, viral infection, or in the 
context of low-grade chronic inflammation34. Based on these observations, we suggest that therapeutic 
strategies that increase FOSL2 expression should be considered for the treatment of allergic diseases. 
 Another example of a gene identified in our analysis and previously implicated in the 
pathophysiology of allergic disease was IL27. This was one of eight genes identified on chromosome 
16p11.2, a region that overlaps a large (~0.45 Mb) and common (49% frequency in Europeans) 
genomic inversion previously reported to be associated with the joint occurrence of asthma and obesity 
35
. Of the two eQTL included in the gene-based test for IL27, one (rs7191548) is in high LD (r2=0.72) 
with a SNP that tags the inversion (rs4788101), suggesting that the association observed with IL27 in 
our study is partly explained by that large structural variant. IL-27 has been shown to suppress Th2 
responses 36, 37, and so has been suggested as a potential new therapy for asthma. However, to our 
knowledge, no clinical trials have been performed to test this possibility. Our observation that, for both 
IL27 eQTL tested, the allele associated with reduced disease risk was associated with increased gene 
expression in blood provides further support for an anti-inflammatory effect of IL-27 for the treatment 
of allergic conditions. 
Lastly, we identified four significant gene-based associations with non-coding RNAs of 















close proximity (8kb) to IKBKE, a regulator of the NF-kappaB pathway that plays a role in immune-
related mechanisms 38, 39. Using data from release v7 of the GTEx project40, we found a highly 
significant positive correlation in gene expression between RP11-534L20.5 and IKBKE in the skin 
(P=10-11), with a weaker but consistent effect in blood and lung (not shown). Such an association could 
arise, for example, if RP11-534L20.5 regulates the expression of IKBKE or if both transcripts share a 
regulatory element. Consistent with the latter hypothesis, the 5’ end of RP11-534L20.5 overlaps a peak 
of H3K27 acetylation (a mark for active enhancers) in multiple cell lines and physically interacts with 
the IKBKE promoter in a B-cell line 41. Further studies are warranted to investigate the function of 
RP11-534L20.5, as well as the other non-coding RNAs identified in our analysis. 
Two additional caveats should be considered when interpreting results from our study. First, our 
original GWAS 6 included only individuals of European ancestry, and so it is unclear if the risk loci 
identified in our current study extend to individuals of other ancestries. Second, the association 
analyses performed to compare individuals suffering from a single allergic disease were based on a 
relatively small sample size, and so it is possible that the lack of significant associations reflects the 
lower power of these analyses.  
In conclusion, we identified significant and reproducible gene-based associations with 19 genes 
located in 11 loci not previously reported in GWAS of allergic disease. Our genetic findings suggest 
that drugs that target these genes might have an increased probability of success if prioritised for 
clinical development 42. Our results further demonstrate the utility of applying gene-based tests of 
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Figure 1. Outline of analytical approach used. 
Figure 2. Summary of association results between allergic disease status and single SNPs or 
individual genes. (A) Single-SNP association results published by Ferreira et al. 6. (B) Single-SNP 
association results obtained after adjusting the results of Ferreira et al. for the effect of the 136 genome-
wide significant associations reported in that study. Variants in four loci (in CADM3, SLC39A8, 
LRRC43 and between KLF5 and KLF12) were genome-wide significant (i.e. P<3x10-8) in the adjusted 
but not in the original GWAS results, and so represent secondary single-SNP association signals in loci 
identified in Ferreira et al. 6. (C) Gene-based association results obtained for 19,432 genes after 
applying the EUGENE approach to results from the adjusted GWAS. Genes with a gene-based 
association P<2.5x10-6 are listed, with font color reflecting the evidence for association with those 
genes in the UK Biobank replication study: green - P<0.0016 (i.e. significant after correcting for 30 
genes tested); blue - 0.0016<P<0.05 (i.e. nominally significant); and black - P>0.05 (i.e. not 
significant). 
Figure 3. Comparison of results obtained with single-SNP and gene-based analyses for the 30 
genes with a significant gene-based P-value (i.e. P<2.5x10-6) in the discovery study. For each gene, 
the x-axis shows the statistical evidence for association (-log10P-value) obtained with the eQTL most 
strongly associated with disease risk. The y-axis shows the evidence for association (-log10P-value) 
obtained for each gene with the EUGENE gene-based approach. Gene names are shown for eight genes 
for which the latter was at least one order of magnitude more significant than the former. The color of 
each circle indicates the number of independent eQTL for that gene that were individually associated 

















Table 1. Association results for 30 genes with a gene-based association P<2.5x10-6 in the discovery analysis. 
Locus Gene 
Gene location  eQTL with strongest 
association in GWAS  
Gene-based analysis: 
discovery (n=360,838)  
Gene-based analysis: 
replication (n=233,898) 















1 CASZ1* 1 10696661  rs12045923 4.9E-07  2 1 1.9E-06  2 1 2.0E-02 
2 OR10J5 1 159504793  rs2427837 1.0E-05  3 3 2.3E-06  3 3 6.3E-07 
3 RP11-534L20.5 1 206677281  rs11117858 8.1E-06  12 5 1.3E-06  11 3 1.1E-03 
4 FOSL2 2 28615315  rs7562 8.8E-07  1 1 8.8E-07  1 1 2.6E-04 
5 
 
RBM15B 3 51428731  rs73078636 1.4E-07  1 1 1.4E-07  1 1 4.0E-04 
VPRBP 3 51433298  rs73078636 1.4E-07  1 1 1.4E-07  1 1 4.0E-04 
6 TICAM2 5 114914339  rs17137937 2.9E-06  3 2 1.7E-06  3 1 5.7E-03 
7 NUP43 6 150045451  rs6909158 7.5E-06  22 6 2.1E-06  22 1 4.5E-01 
8 IPCEF1 6 154475631  rs9397706 4.7E-07  4 3 4.3E-07  4 3 4.1E-07 
9 AC004893.11 7 98610788  rs4236540 8.1E-07  1 1 8.1E-07  1 1 4.3E-04 
10 ABO* 9 136125788  rs550057 2.8E-07  14 5 1.7E-07  14 6 3.8E-10 
11 
 
PTPLA 10 17631958  rs7092926 6.8E-07  4 4 8.2E-07  4 0 2.1E-01 
TMEM236 10 17794251  rs7092926 6.8E-07  3 3 1.9E-06  3 0 3.6E-01 
12 PRR5L 11 36317838  rs7925585 2.8E-06  6 2 9.7E-07  6 2 1.4E-06 









APOBR 16 28505970  rs151233 3.2E-06  2 2 1.6E-08  2 2 3.8E-05 
IL27 16 28510683  rs231970 4.8E-06  2 2 2.6E-08  2 2 1.6E-04 
SULT1A1 16 28616903  rs75539558 1.6E-06  8 3 2.0E-07  8 4 1.4E-05 
ATXN2L 16 28834356  rs8056890 1.7E-06  1 1 1.7E-06  1 1 1.7E-04 
RP11-24N18.1 16 28841933  rs8056890 1.7E-06  1 1 1.7E-06  1 1 1.7E-04 
SPNS1 16 28985542  rs2726040 4.8E-06  15 6 3.5E-09  14 5 7.4E-04 
RP11-264B17.4 16 28986294  rs8045689 6.3E-06  3 2 1.1E-06  3 2 1.5E-03 
LAT 16 28996147  rs8045689 6.3E-06  3 2 1.1E-06  3 3 2.4E-04 




ICAM1 19 10381511  rs1799969 1.8E-05  12 7 5.1E-07  12 0 4.1E-01 
CTD-2369P2.8 19 10396477  rs1799969 1.8E-05  12 7 5.1E-07  12 0 4.1E-01 
ICAM4 19 10397643  rs1799969 1.8E-05  12 7 6.1E-07  11 0 4.9E-01 
17 FPR1 19 52248425  rs7254019 1.8E-05  14 7 1.5E-08  14 3 3.2E-03 















 NCF4 22 37257030  rs4821544 3.6E-07  5 2 4.8E-08  5 3 1.1E-04 
* Located in a locus identified in a previous GWAS of allergic disease 43 
The replication P-value is in bold if significant after correcting for the 30 genes tested (i.e. P<0.05/30=0.0016) and in italic if 0.0016<P<0.05 
















Table 2. Genes with a known function that is relevant to the pathophysiology of allergic disease. 
Gene Relevant function References 
FOSL2 B cell and epidermal differentiation, Th17 and adipocyte function 31-33, 44 
VPRBP T cell function, B cell development, viral replication 45-47 
IPCEF1 Binds cytohesin 2, which is involved in IL-1beta signaling and cell adhesion 48-50 
PRR5L mTOR interactor that regulates cell death 51 
NCF4 Phagocyte oxidative burst, antigen presentation 52, 53 
APOBR Macrophage receptor for apolipoprotein B48 54 
IL27 Regulation of Th1 and Th2 reponses, Treg function, epithelial cell proliferation 37, 55-57 
ATXN2L Cytokine signaling 58 





















































With all three diseases
A+H-E- A-H+E- A-H-E+ A+H+E- A+H-E+ A-H+E+ A+H+E+
UKBiobank Population-based NA 138354 96108 42246 8769 4838 1538 1661 596 439 364 24041 3060 56.7 (39-73) 53 30.3 (1-73) 24.4 (1-70) 25.6 (1-69)
23andMe Population-based NA 118269 34934 83335 2048 26125 3648 8574 365 4193 3610 34772 16742 49.5 (1-114) 48 20.8 (0-93) NA 23.6 (0-96)
GERA Population-based NA 51218 15999 35219 4439 17401 2297 7836 416 1839 991 0 11082 62.3 (18-90) 59 NA NA NA
CATSS Population-based NA 11068 7488 3580 1600 380 681 387 240 98 194 0 919 9.8 (9-23) 49 4.2 (0-23) 5.0 (0-11) 1.5 (0-11)
NTR Population-based NA 10242 7919 2323 685 837 219 421 64 48 49 0 582 40.1 (4-94) 64 NA NA NA
LifeLines Population-based NA 8560 4837 3723 190 1718 897 245 58 468 113 34 884 46.2 (18-88) 58 17.8 (0-66) 23.4 (0-88) NA
TWINGENE Population-based NA 5517 3762 1755 1007 418 79 219 21 5 6 0 251 58.3 (41-93) 51 54.1 (0-93) 24.9 (0-72) 1.5 (0-45)
ALSPAC$ Population-based NA 4964 2330 2634 373 620 374 224 139 187 187 530 737 A/E: 10.8 (10-13); H: 13.9 (13-16) 49 NA NA NA
SALTY Population-based NA 4062 2761 1301 583 365 79 226 27 14 7 0 274 49.8 (41-72) 49 41.6 (0-72) 20.3 (0-52) 8.9 (0-46)
AAGC Selected case-control Asthma 2435 460 1975 393 124 32 701 156 14 555 0 1426 35.1 (3-89) 56 15.5 (0-75) NA 6.7 (0-40)
GENEVA Selected case-control Eczema 2633 1274 1359 41 154 383 29 65 309 289 89 692 43.9 (0-85) 56 NA NA 11.7 (0-85)
GENUFAD-SHIP-1 Selected case-control Eczema 1781 1364 417 0 0 323 0 46 26 22 0 94 Cases: 3.9 (1-34); Controls: 50.0 (20-81) Cases: 39; Controls: 50 7 (1-31) 8 (2-31) 1 (0-2)
GENUFAD-SHIP-2 Selected case-control Eczema 1735 1473 262 0 0 169 0 35 27 31 0 93 Cases: 8.3 (1-26); Controls: 50.0 (20-81) Cases: 54; Controls: 50 11 (2-24) 13 (1-26) 1 (0-2)
Total 360838 180709 180129 20128 52980 10719 20523 2228 7667 6418 59466 36836
# Individuals with missing information for at least one disease could not be classified into one of the seven three-disease groups.
$ For ALSPAC, information from different surveys was used to define asthma (A) and eczema (E) when compared to those used to define hay fever. For this reason, age of participants is reported separately for A/E and H.
Age (mean, range) % Females
Mean age-of-onset (range)
Total With only a single disease With two diseases Unclassifiable# Asthma Hay fever Eczema
Table E1. Thirteen studies that contributed to the GWAS of allergic disease reported by Ferreira et al. 2017.
Study Study-type Original case 
ascertainment N total N controls
Number of cases














Table E2Table E2. Genome-wide association studies of gene expression levels queried to identify expression quantitative trait loci (i.e. eQTL)
N genes N associations P<2.3x10-9
Andiappan 26259071 NEUTROPHILS 114 310 3776
Barreiro 22233810 DENDRITIC-NotInfected 65 36 36
DENDRITIC-TBInfected 65 216 216
Battle 24092820 WHOLE-BLOOD 922 7792 7793
WHOLE-BLOOD-ase 922 310 537
WHOLE-BLOOD-splice 922 532 818
Brumpton 27155841 LCLS 356 27 2139
Caliskan 25874939 PBMCS-baseline 98 173 173
PBMCS-rhinovirus 98 169 169
PBMCS-rhinovirus-reQTL 98 12 12
Davenport 26917434 LEUCOCYTES 265 879 7699
Dimas 19644074 LCLS 75 97 121
TCELLS 75 85 107
FIBROBLASTS 75 102 136
Di Narzo 27336838 WHOLE-BLOOD 149 1195 2220
Ding 21129726 LESIONAL-SKIN 57 15 295
NORMAL-SKIN 53 19 350
UNINVOLVED-SKIN 53 12 160
Dixon 17873877 LCLS 400 634 6735
Fairfax 2012 22446964 BCELLS 283 236 1723
MONOCYTES 283 549 4051
Fairfax 2014 24604202 MONOCYTES-IFN 367 2048 21366
MONOCYTES-LPS2 261 686 4658
MONOCYTES-LPS24 322 1412 10740
MONOCYTES-NAIVE 414 2024 24676
Fehrmann 21829388 WHOLE-BLOOD 1469 2944 23614
Ferraro 24610777 Tconv 65 26 118
Tregs 65 24 105
Franco 23878721 WHOLE-BLOOD-Influenza 247 65 329
Lappalainen 24037378 LCLS 373 3525 1397237
Grundberg 22941192 LCLS 856 1550 68025
SKIN 856 879 31390
GTEx 25954001 FIBROBLASTS 272 3910 368252
LCLS 114 1062 88242
LUNG 278 3148 335019














Table E2SKIN 302 4026 613093
SPLEEN 89 926 74864
WHOLE-BLOOD 338 3331 343913
Hao 23209423 LUNG 1111 4177 6339
Huang 25951796 LCLs 368 2196 3091
PBMCs 240 1939 2617
SKIN 110 384 453
Jansen Under Review WHOLE-BLOOD 4896 4377 7460
Kasela 28248954 CD4TCELLS 293 1256 121508
CD8TCELLS 293 947 83337
Kim 25327457 MONOCYTES-Baseline 137 681 5669
MONOCYTES-Differential 137 62 377
MONOCYTES-LPS 137 554 4802
Kukurba 27197214 WHOLE-BLOOD 922 90 8333
Lee 24604203 DENDRITIC-Baseline 528 82 82
DENDRITIC-Flu 342 105 105
DENDRITIC-Flu-delta 342 44 44
DENDRITIC-IFNb 284 86 86
DENDRITIC-IFNb-delta 284 23 24
DENDRITIC-LPS 356 96 96
DENDRITIC-LPS-delta 356 31 31
LloydJones 28065468 WHOLE-BLOOD 2765 5669 1373201
Luo 26102239 SMALL-AIRWAYS 105 152 174
Murphy 20833654 CD4-TCELLS 200 294 986
Naranbhai 26151758 NEUTROPHILS 101 493 547
Nedelec 27768889 MACROPHAGES-baseline 95 451 451
MACROPHAGES-baseline-asQTL 95 634 951
MACROPHAGES-listeria 95 422 422
MACROPHAGES-listeria-asQTL 95 557 827
MACROPHAGES-listeria-reQTL 95 93 93
MACROPHAGES-salmonella 95 433 434
MACROPHAGES-salmonella-asQTL 95 487 741
MACROPHAGES-salmonella-reQTL 95 199 199
Peters 27015630 BCELLS 80 66 318
CD4-TCELLS 121 396 2187
CD8-TCELLS 108 277 1484
MONOCYTES 124 564 3254














Table E2Quach 27768888 MONOCYTES-baseline 100 467 469
MONOCYTES-IAV 100 366 366
MONOCYTES-LPS 100 464 465
MONOCYTES-Pam3CSK4 100 536 537
MONOCYTES-R848 100 478 479
Raj 24786080 CD4-TCELLS 407 1898 150019
MONOCYTES 401 2494 196870
Walsh 27140173 WHOLE-BLOOD 377 3777 546913
Westra 24013639 WHOLE-BLOOD 5311 4285 343167
Yao 28285768 WHOLEBLOOD 5257 1681 93834
Ye 25214635 CD4-TCELLS-48h328 348 51 51
CD4-TCELLS-48hTh17 348 45 45
CD4-TCELLS-4h328 348 24 24
CD4-TCELLS-4hIFNb 348 27 27
CD4-TCELLS-UNST 348 19 19
Zeller 20502693 MONOCYTES 1490 2322 31353
Zhernakova 27918533 WHOLEBLOOD-exon-primary 2116 15028 88928
WHOLEBLOOD-exonratio-primary 2116 6064 20222
WHOLEBLOOD-gene-contextspecific 2116 14670 27186
WHOLEBLOOD-gene-primary 2116 15158 3669632














Table E3Table E3. eQTL included in the gene based test for each of the 30 genes identified in the discovery study.




























































Table E4Table E4. Association results for each eQTL included in the gene-based test of each of the 30 genes identified in the discovery analysis.
Proxy tested P-value Effect allele Other allele Effect allele frequency Beta eQTL eQTL study and tissue P-value Effect allele Effect
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-gene-primary 6.05E-142 T -25.3655
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-gene-contextspecific 6.05E-142 T -25.3655
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exon-primary 6.54E-133 T -24.5331
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exonratio-primary 1.53E-29 T -11.2868
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exon-primary 1.04E-27 T -10.9092
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exon-primary 8.92E-27 T -10.712
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exon-primary 4.48E-26 T -10.5617
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exonratio-primary 8.08E-24 T -10.0626
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Zhernakova_WHOLEBLOOD-exonratio-primary 1.85E-23 T -9.98077
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 Yao_WHOLEBLOOD 1.28E-11 C 0.0253396
ABO 1.74E-07 rs550057 2.77E-07 T C 0.2806 0.0294 rs550057 GTE_WHOLEBLOOD 3.45E-10 T -0.53797
ABO 1.74E-07 rs176694 1.15E-05 T G 0.8895 -0.0376 rs176694 Zhernakova_WHOLEBLOOD-gene-primary 8.37E-25 G -10.2834
ABO 1.74E-07 rs28645493 0.000417512 C G 0.9031 -0.0328 rs28645493 Zhernakova_WHOLEBLOOD-gene-primary 8.86E-32 G -11.7307
ABO 1.74E-07 rs4962050 0.00159826 C G 0.3078 -0.0180 rs4962050 Zhernakova_WHOLEBLOOD-gene-primary 4.50E-25 C 10.343
ABO 1.74E-07 rs12683493 0.00756848 T C 0.1990 -0.0166 rs12683493 Zhernakova_WHOLEBLOOD-gene-primary 1.39E-11 T 6.75868
ABO 1.74E-07 rs9411490 0.0892349 A G 0.8214 0.0109 rs9411490 Zhernakova_WHOLEBLOOD-gene-contextspecific 2.57E-16 G -8.19194
ABO 1.74E-07 rs12379977 0.265942 T C 0.3299 -0.0061 rs12379977 Zhernakova_WHOLEBLOOD-gene-primary 2.72E-18 T 8.72254
ABO 1.74E-07 rs10901244 0.364805 T C 0.4184 -0.0046 rs10901244 Hao_LUNG 0 T -8.47
ABO 1.74E-07 rs626035 0.443795 T G 0.8027 0.0048 rs626035 Zhernakova_WHOLEBLOOD-gene-primary 1.91E-17 G 8.49909
ABO 1.74E-07 rs9411463 0.492101 T C 0.0867 -0.0069 rs9411463 Hao_LUNG 0 C -11.7
ABO 1.74E-07 rs9411463 0.492101 T C 0.0867 -0.0069 rs9411463 Zhernakova_WHOLEBLOOD-gene-primary 2.39E-73 T 18.1159
ABO 1.74E-07 rs9411463 0.492101 T C 0.0867 -0.0069 rs9411463 GTE_SKIN 6.54E-20 T 1.12925
ABO 1.74E-07 rs9411463 0.492101 T C 0.0867 -0.0069 rs9411463 GTE_SKIN 1.00E-17 T 1.38294
ABO 1.74E-07 rs9411463 0.492101 T C 0.0867 -0.0069 rs9411463 GTE_LUNG 7.67E-12 T 0.626984
ABO 1.74E-07 rs35664240 0.592636 T C 0.1105 0.0052 rs35664240 Zhernakova_WHOLEBLOOD-gene-primary 2.39E-12 T -7.00975
ABO 1.74E-07 rs62576042 0.625485 T C 0.1701 0.0037 rs62576042 Zhernakova_WHOLEBLOOD-gene-primary 2.18E-21 T 9.49601
ABO 1.74E-07 rs623361 0.635394 A G 0.3350 0.0028 rs623361 Zhernakova_WHOLEBLOOD-gene-primary 4.77E-11 A 6.57812
ABO 1.74E-07 rs3094377 0.875632 T C 0.0340 -0.0021 rs3094377 Zhernakova_WHOLEBLOOD-gene-primary 1.39E-18 T -8.7985
AC004893.11 8.10E-07 rs4236540 8.10E-07 T G 0.7143 -0.0282 rs4236540 Zhernakova_WHOLEBLOOD-exon-primary 3.67E-15 G 7.86572
AC004893.11 8.10E-07 rs4236540 8.10E-07 T G 0.7143 -0.0282 rs4236540 Zhernakova_WHOLEBLOOD-gene-primary 1.16E-13 G 7.42145
AC004893.11 8.10E-07 rs4236540 8.10E-07 T G 0.7143 -0.0282 rs4236540 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.16E-13 G 7.42145
APOBR 1.58E-08 rs151233 3.22E-06 T C 0.1327 0.0385 rs151233 Zhernakova_WHOLEBLOOD-exon-primary 2.31E-12 T -7.0144
APOBR 1.58E-08 rs151233 3.22E-06 T C 0.1327 0.0385 rs151233 Zhernakova_WHOLEBLOOD-exon-primary 1.47E-11 T -6.75084
APOBR 1.58E-08 rs151233 3.22E-06 T C 0.1327 0.0385 rs151233 Zhernakova_WHOLEBLOOD-gene-contextspecific 9.17E-10 T -6.12304
APOBR 1.58E-08 rs151233 3.22E-06 T C 0.1327 0.0385 rs151233 Zhernakova_WHOLEBLOOD-gene-primary 9.17E-10 T -6.12304
APOBR 1.58E-08 rs27741 4.42E-06 A G 0.3622 -0.0239 rs27741 LloydJones_WHOLEBLOOD 9.90E-30 A 0.313874
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-contextspecific 2.10E-23 A -9.96813
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-primary 2.10E-23 A -9.96813
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-exon-primary 3.78E-22 A -9.67673
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-primary 1.27E-20 A -9.31092
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.27E-20 A -9.31092
ATXN2L 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-exon-primary 4.79E-14 A -7.53739
CASZ1 1.93E-06 rs12045923 4.87E-07 T C 0.6497 0.0288 rs12045923 Kim_MONOCYTES-LPS 7.63E-12 NA -9
CASZ1 1.93E-06 rs12045923 4.87E-07 T C 0.6497 0.0288 rs12045923 Kim_MONOCYTES-Baseline 3.72E-11 NA -9
CASZ1 1.93E-06 rs284296 0.29118 A G 0.7823 -0.0070 rs284296 LloydJones_WHOLEBLOOD 7.10E-18 G -0.282965
CASZ1 1.93E-06 rs284296 0.29118 A G 0.7823 -0.0070 rs284296 Zhernakova_WHOLEBLOOD-exonratio-primary 3.41E-10 G 6.27892
CTD-2369P2.8 5.10E-07 rs1799969 1.76E-05 A G 0.1480 0.0355 rs1799969 Zhernakova_WHOLEBLOOD-gene-primary 2.10E-14 A -7.64456
CTD-2369P2.8 5.10E-07 rs78064630 0.00135441 A G 0.0765 -0.0314 rs78064630 Zhernakova_WHOLEBLOOD-gene-primary 2.46E-12 A 7.00583
Single-SNP association results with allergic disease in the adjusted GWAS
Gene EUGENE gene-based P-value














Table E4CTD-2369P2.8 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 2.96E-190 T 29.421
CTD-2369P2.8 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.17E-181 T 28.7411
CTD-2369P2.8 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-primary 1.17E-181 T 28.7411
CTD-2369P2.8 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 GTE_WHOLEBLOOD 4.51E-21 T 0.410584
CTD-2369P2.8 5.10E-07 rs2633973 0.00276867 T C 0.6599 -0.0168 rs2633973 Zhernakova_WHOLEBLOOD-gene-primary 8.83E-10 C -6.12904
CTD-2369P2.8 5.10E-07 rs28378712 0.00678241 T G 0.6803 -0.0152 rs28378712 Zhernakova_WHOLEBLOOD-gene-primary 3.55E-19 G -8.94992
CTD-2369P2.8 5.10E-07 rs2017213 0.0075857 A T 0.3810 -0.0139 rs2017213 Zhernakova_WHOLEBLOOD-gene-primary 6.90E-12 A 6.85981
CTD-2369P2.8 5.10E-07 rs10411056 0.0197799 A C 0.9354 0.0226 rs10411056 Zhernakova_WHOLEBLOOD-gene-primary 2.83E-15 C 7.89849
CTD-2369P2.8 5.10E-07 rs79337061 0.348043 T C 0.0765 -0.0091 rs79337061 Zhernakova_WHOLEBLOOD-gene-primary 3.58E-15 T 7.86884
CTD-2369P2.8 5.10E-07 rs2358581 0.352461 T G 0.2483 -0.0056 rs2358581 Zhernakova_WHOLEBLOOD-gene-primary 1.63E-27 T -10.8681
CTD-2369P2.8 5.10E-07 rs62130661 0.464875 C G 0.8010 0.0047 rs62130661 Zhernakova_WHOLEBLOOD-gene-primary 6.30E-30 G 11.3644
CTD-2369P2.8 5.10E-07 rs77123125 0.758586 A G 0.1003 -0.0032 rs77123125 Zhernakova_WHOLEBLOOD-gene-primary 7.17E-10 A -6.16239
CTD-2369P2.8 5.10E-07 rs3177696 0.908246 T C 0.9201 -0.0010 rs3177696 Zhernakova_WHOLEBLOOD-gene-primary 3.44E-15 C 7.874
FOSL2 8.76E-07 rs7562 8.76E-07 T C 0.5306 0.0251 rs7562 Zhernakova_WHOLEBLOOD-exonratio-primary 2.60E-29 C -11.2398
FOSL2 8.76E-07 rs7562 8.76E-07 T C 0.5306 0.0251 rs7562 Zhernakova_WHOLEBLOOD-exonratio-primary 6.14E-26 C 10.5324
FOSL2 8.76E-07 rs7562 8.76E-07 T C 0.5306 0.0251 rs7562 Walsh_WHOLEBLOOD 1.89E-11 T -0.47246
FOSL2 8.76E-07 rs7562 8.76E-07 T C 0.5306 0.0251 rs7562 Zhernakova_WHOLEBLOOD-exonratio-primary 1.41E-09 C 6.05473
FPR1 1.49E-08 rs7254019 1.79E-05 A G 0.1395 0.0381 rs7254019 Zhernakova_WHOLEBLOOD-gene-primary 1.45E-10 A -6.41041
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Zhernakova_WHOLEBLOOD-exon-primary 1.83E-150 G -26.1263
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Zhernakova_WHOLEBLOOD-gene-primary 4.30E-132 G -24.4563
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Zhernakova_WHOLEBLOOD-exon-primary 6.10E-121 G -23.3847
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 LloydJones_WHOLEBLOOD 7.10E-80 G -0.532809
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Zhernakova_WHOLEBLOOD-exon-primary 4.02E-45 G -14.096
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Zhernakova_WHOLEBLOOD-exon-primary 3.32E-20 G -9.20782
FPR1 1.49E-08 rs12461801 9.65E-05 A G 0.5969 -0.0203 rs12461801 Walsh_WHOLEBLOOD 5.91E-14 G -0.538086
FPR1 1.49E-08 rs6509571 0.000191405 T C 0.3520 -0.0198 rs6509571 Westra_WHOLEBLOOD 7.86E-73 T 18.0502
FPR1 1.49E-08 rs6509571 0.000191405 T C 0.3520 -0.0198 rs6509571 LloydJones_WHOLEBLOOD 1.60E-38 T 0.373842
FPR1 1.49E-08 rs6509571 0.000191405 T C 0.3520 -0.0198 rs6509571 Zhernakova_WHOLEBLOOD-gene-primary 3.51E-34 T 12.1901
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 Hao_LUNG 0 G 10.3
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 Zhernakova_WHOLEBLOOD-gene-primary 5.36E-93 A -20.4556
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 Zeller_MONOCYTES 6.54E-92 NA -9
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 Westra_WHOLEBLOOD 6.06E-90 A -20.11
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 LloydJones_WHOLEBLOOD 3.50E-48 A -0.441034
FPR1 1.49E-08 rs7253284 0.000877773 A G 0.3282 0.0180 rs7253284 GTE_WHOLEBLOOD 1.35E-09 G 0.1661
FPR1 1.49E-08 rs62106945 0.00554085 T C 0.0884 0.0252 rs62106945 Zhernakova_WHOLEBLOOD-gene-primary 1.73E-11 T -6.7268
FPR1 1.49E-08 rs16983230 0.0164076 T G 0.9558 -0.0316 rs16983230 Westra_WHOLEBLOOD 3.93E-10 G -6.25665
FPR1 1.49E-08 rs79956121 0.0172967 T C 0.0714 0.0277 rs79956121 Zhernakova_WHOLEBLOOD-gene-primary 2.37E-10 T -6.33492
FPR1 1.49E-08 rs1868943 0.0584274 A G 0.0986 0.0170 rs1868943 Zhernakova_WHOLEBLOOD-gene-primary 8.29E-31 A -11.54
FPR1 1.49E-08 rs1868943 0.0584274 A G 0.0986 0.0170 rs1868943 Zhernakova_WHOLEBLOOD-exon-primary 1.29E-19 A -9.06152
FPR1 1.49E-08 rs17661285 0.0848097 A G 0.3163 -0.0095 rs17661285 Westra_WHOLEBLOOD 3.20E-25 A 10.376
FPR1 1.49E-08 rs17661285 0.0848097 A G 0.3163 -0.0095 rs17661285 LloydJones_WHOLEBLOOD 9.60E-13 A 0.211433
FPR1 1.49E-08 rs8110040 0.568977 A G 0.0884 0.0050 rs8110040 Westra_WHOLEBLOOD 5.78E-17 A -8.36968
FPR1 1.49E-08 rs8104640 0.573427 T C 0.1207 0.0050 rs8104640 Westra_WHOLEBLOOD 4.18E-108 T 22.0876
FPR1 1.49E-08 rs8104640 0.573427 T C 0.1207 0.0050 rs8104640 LloydJones_WHOLEBLOOD 1.00E-61 T 0.795929
FPR1 1.49E-08 rs8104640 0.573427 T C 0.1207 0.0050 rs8104640 Walsh_WHOLEBLOOD 4.66E-28 C 1.2629
FPR1 1.49E-08 rs8104640 0.573427 T C 0.1207 0.0050 rs8104640 GTE_FIBROBLASTS 7.55E-18 T 0.748262
FPR1 1.49E-08 rs17803207 0.624261 A G 0.1122 -0.0037 rs17803207 Zhernakova_WHOLEBLOOD-exon-primary 2.36E-191 A 29.5069
FPR1 1.49E-08 rs17803207 0.624261 A G 0.1122 -0.0037 rs17803207 Zhernakova_WHOLEBLOOD-exonratio-primary 2.23E-61 A 16.5302
FPR1 1.49E-08 rs17803207 0.624261 A G 0.1122 -0.0037 rs17803207 Battle_WHOLEBLOOD-ase 4.72E-53 NA -9
FPR1 1.49E-08 rs17803207 0.624261 A G 0.1122 -0.0037 rs17803207 Zhernakova_WHOLEBLOOD-exon-primary 1.54E-12 A 7.07069
FPR1 1.49E-08 rs117223215 0.721224 T C 0.0153 0.0055 rs117223215 LloydJones_WHOLEBLOOD 3.90E-20 T -0.776936
FPR1 1.49E-08 rs73056872 0.919279 T G 0.9133 -0.0009 rs73056872 LloydJones_WHOLEBLOOD 1.20E-15 G -0.406202
ICAM1 5.10E-07 rs1799969 1.76E-05 A G 0.1480 0.0355 rs1799969 Zhernakova_WHOLEBLOOD-gene-primary 2.10E-14 A -7.64456
ICAM1 5.10E-07 rs78064630 0.00135441 A G 0.0765 -0.0314 rs78064630 Zhernakova_WHOLEBLOOD-gene-primary 2.46E-12 A 7.00583
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 2.96E-190 T 29.421
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.17E-181 T 28.7411













Table E4ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Raj_MONOCYTES 4.09E-94 NA -9
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Battle_WHOLEBLOOD 3.16E-44 NA -9
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-primary 3.14E-30 T 11.4249
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 1.62E-28 T 11.0773
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 3.29E-26 T 10.5908
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 7.79E-26 T 10.5098
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-primary 2.07E-21 T 9.50136
ICAM1 5.10E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 1.46E-13 T 7.39063
ICAM1 5.10E-07 rs2633973 0.00276867 T C 0.6599 -0.0168 rs2633973 Zhernakova_WHOLEBLOOD-gene-primary 8.83E-10 C -6.12904
ICAM1 5.10E-07 rs28378712 0.00678241 T G 0.6803 -0.0152 rs28378712 Zhernakova_WHOLEBLOOD-gene-primary 3.55E-19 G -8.94992
ICAM1 5.10E-07 rs2017213 0.0075857 A T 0.3810 -0.0139 rs2017213 Zhernakova_WHOLEBLOOD-gene-primary 6.90E-12 A 6.85981
ICAM1 5.10E-07 rs10411056 0.0197799 A C 0.9354 0.0226 rs10411056 Zhernakova_WHOLEBLOOD-gene-primary 2.83E-15 C 7.89849
ICAM1 5.10E-07 rs79337061 0.348043 T C 0.0765 -0.0091 rs79337061 Zhernakova_WHOLEBLOOD-gene-primary 3.58E-15 T 7.86884
ICAM1 5.10E-07 rs2358581 0.352461 T G 0.2483 -0.0056 rs2358581 Zhernakova_WHOLEBLOOD-gene-primary 1.63E-27 T -10.8681
ICAM1 5.10E-07 rs62130661 0.464875 C G 0.8010 0.0047 rs62130661 Zhernakova_WHOLEBLOOD-gene-primary 6.30E-30 G 11.3644
ICAM1 5.10E-07 rs77123125 0.758586 A G 0.1003 -0.0032 rs77123125 Zhernakova_WHOLEBLOOD-gene-primary 7.17E-10 A -6.16239
ICAM1 5.10E-07 rs3177696 0.908246 T C 0.9201 -0.0010 rs3177696 Zhernakova_WHOLEBLOOD-gene-primary 3.44E-15 C 7.874
ICAM4 6.08E-07 rs1799969 1.76E-05 A G 0.1480 0.0355 rs1799969 Zhernakova_WHOLEBLOOD-gene-primary 2.10E-14 A -7.64456
ICAM4 6.08E-07 rs1799969 1.76E-05 A G 0.1480 0.0355 rs1799969 Westra_WHOLEBLOOD 8.91E-11 A -6.48453
ICAM4 6.08E-07 rs78064630 0.00135441 A G 0.0765 -0.0314 rs78064630 Zhernakova_WHOLEBLOOD-gene-primary 2.46E-12 A 7.00583
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Battle_WHOLEBLOOD 1.06E-216 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-exon-primary 2.96E-190 T 29.421
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.17E-181 T 28.7411
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Zhernakova_WHOLEBLOOD-gene-primary 1.17E-181 T 28.7411
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Fairfax_MONOCYTES-NAIVE 2.35E-129 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Westra_WHOLEBLOOD 2.04E-120 T 23.3333
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 LloydJones_WHOLEBLOOD 9.10E-100 T 0.663692
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Fairfax_MONOCYTES-NAIVE 5.49E-97 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Fairfax_MONOCYTES 2.77E-92 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Fairfax_MONOCYTES 7.46E-62 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Westra_WHOLEBLOOD 8.86E-54 T 15.4397
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 LloydJones_WHOLEBLOOD 6.30E-38 T 0.400262
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Walsh_WHOLEBLOOD 1.28E-37 C -0.967882
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 GTE_WHOLEBLOOD 1.83E-34 T 0.619615
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Grundberg_LCLS 1.43E-16 T -0.100867
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Davenport_LEUCOCYTES 4.91E-11 NA -9
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Yao_WHOLEBLOOD 2.19E-10 C -0.045635
ICAM4 6.08E-07 rs281437 0.00184684 T C 0.2670 -0.0178 rs281437 Yao_WHOLEBLOOD 2.19E-10 C -0.045635
ICAM4 6.08E-07 rs2633973 0.00276867 T C 0.6599 -0.0168 rs2633973 Zhernakova_WHOLEBLOOD-gene-primary 8.83E-10 C -6.12904
ICAM4 6.08E-07 rs28378712 0.00678241 T G 0.6803 -0.0152 rs28378712 Zhernakova_WHOLEBLOOD-gene-primary 3.55E-19 G -8.94992
ICAM4 6.08E-07 rs2017213 0.0075857 A T 0.3810 -0.0139 rs2017213 Zhernakova_WHOLEBLOOD-gene-primary 6.90E-12 A 6.85981
ICAM4 6.08E-07 rs10411056 0.0197799 A C 0.9354 0.0226 rs10411056 Zhernakova_WHOLEBLOOD-gene-primary 2.83E-15 C 7.89849
ICAM4 6.08E-07 rs10411056 0.0197799 A C 0.9354 0.0226 rs10411056 LloydJones_WHOLEBLOOD 9.30E-12 C 0.359728
ICAM4 6.08E-07 rs2358581 0.352461 T G 0.2483 -0.0056 rs2358581 Zhernakova_WHOLEBLOOD-gene-primary 1.63E-27 T -10.8681
ICAM4 6.08E-07 rs2358581 0.352461 T G 0.2483 -0.0056 rs2358581 LloydJones_WHOLEBLOOD 1.00E-13 T -0.222958
ICAM4 6.08E-07 rs7252450 0.397785 A C 0.0782 -0.0082 rs7252450 LloydJones_WHOLEBLOOD 3.40E-15 A 0.413387
ICAM4 6.08E-07 rs7252450 0.397785 A C 0.0782 -0.0082 rs7252450 Zhernakova_WHOLEBLOOD-gene-primary 1.19E-11 A 6.78206
ICAM4 6.08E-07 rs62130661 0.464875 C G 0.8010 0.0047 rs62130661 Zhernakova_WHOLEBLOOD-gene-primary 6.30E-30 G 11.3644
ICAM4 6.08E-07 rs62130661 0.464875 C G 0.8010 0.0047 rs62130661 LloydJones_WHOLEBLOOD 1.90E-16 G 0.285605
ICAM4 6.08E-07 rs77123125 0.758586 A G 0.1003 -0.0032 rs77123125 Zhernakova_WHOLEBLOOD-gene-primary 7.17E-10 A -6.16239
ICAM4 6.08E-07 rs3177696 0.908246 T C 0.9201 -0.0010 rs3177696 Zhernakova_WHOLEBLOOD-gene-primary 3.44E-15 C 7.874
ICAM4 6.08E-07 rs3177696 0.908246 T C 0.9201 -0.0010 rs3177696 LloydJones_WHOLEBLOOD 1.10E-10 C 0.314191
IL27 2.60E-08 rs231970 4.84E-06 A G 0.8827 -0.0350 rs231970 Zhernakova_WHOLEBLOOD-gene-primary 4.80E-21 G -9.41324
IL27 2.60E-08 rs7191548 1.18E-05 T C 0.6599 0.0237 rs7191548 Zhernakova_WHOLEBLOOD-gene-primary 4.30E-36 C 12.5439
IL27 2.60E-08 rs7191548 1.18E-05 T C 0.6599 0.0237 rs7191548 Zhernakova_WHOLEBLOOD-gene-contextspecific 4.30E-36 C 12.5439
IL27 2.60E-08 rs7191548 1.18E-05 T C 0.6599 0.0237 rs7191548 Zhernakova_WHOLEBLOOD-exon-primary 3.14E-20 C 9.21402













Table E4IPCEF1 4.33E-07 rs7759388 0.00300347 A G 0.1599 0.0200 rs7759388 Zhernakova_WHOLEBLOOD-exon-primary 1.51E-23 A -10.0008
IPCEF1 4.33E-07 rs7759388 0.00300347 A G 0.1599 0.0200 rs7759388 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.99E-19 A -9.01372
IPCEF1 4.33E-07 rs7759388 0.00300347 A G 0.1599 0.0200 rs7759388 Zhernakova_WHOLEBLOOD-gene-primary 1.99E-19 A -9.01372
IPCEF1 4.33E-07 rs7759388 0.00300347 A G 0.1599 0.0200 rs7759388 Battle_WHOLEBLOOD 2.78E-10 NA -9
IPCEF1 4.33E-07 rs1406055 0.0498256 C G 0.3214 0.0110 rs1406055 Zhernakova_WHOLEBLOOD-exon-primary 2.26E-153 C 26.3811
IPCEF1 4.33E-07 rs1406055 0.0498256 C G 0.3214 0.0110 rs1406055 Zhernakova_WHOLEBLOOD-exonratio-primary 5.96E-128 C 24.0642
IPCEF1 4.33E-07 rs12528985 0.676521 T C 0.3486 -0.0021 rs12528985 GTE_SKIN 1.39E-10 T -0.363454
LAT 1.06E-06 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Fehrmann_WHOLEBLOOD 5.40E-177 G 28.37
LAT 1.06E-06 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-primary 4.73E-19 C 8.91852
LAT 1.06E-06 rs6565261 0.000208433 A C 0.2721 0.0212 rs6565261 Fehrmann_WHOLEBLOOD 2.40E-21 A -9.48
LAT 1.06E-06 rs4788115 0.122264 A T 0.2160 0.0112 rs4788115 Zhernakova_WHOLEBLOOD-exon-primary 3.58E-23 A 9.91507
LAT 1.06E-06 rs4788115 0.122264 A T 0.2160 0.0112 rs4788115 Zhernakova_WHOLEBLOOD-exon-primary 1.57E-16 A -8.25109
LAT 1.06E-06 rs4788115 0.122264 A T 0.2160 0.0112 rs4788115 Zhernakova_WHOLEBLOOD-gene-primary 3.93E-10 A -6.25655
MYO1C 1.52E-06 rs56157500 9.23E-05 A C 0.7738 -0.0239 rs56157500 Zhernakova_WHOLEBLOOD-gene-primary 3.06E-12 C 6.97484
MYO1C 1.52E-06 rs59343110 9.79E-05 T C 0.0748 -0.0338 rs59343110 Zhernakova_WHOLEBLOOD-gene-primary 1.82E-13 T 7.36164
MYO1C 1.52E-06 rs59343110 9.79E-05 T C 0.0748 -0.0338 rs59343110 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.84E-11 T 6.71784
MYO1C 1.52E-06 rs147003567 0.0395452 A G 0.0595 0.0206 rs147003567 Zhernakova_WHOLEBLOOD-gene-contextspecific 2.26E-22 A -9.72914
MYO1C 1.52E-06 rs147003567 0.0395452 A G 0.0595 0.0206 rs147003567 Zhernakova_WHOLEBLOOD-gene-primary 2.26E-22 A -9.72914
MYO1C 1.52E-06 rs147003567 0.0395452 A G 0.0595 0.0206 rs147003567 Zhernakova_WHOLEBLOOD-exon-primary 1.42E-20 A -9.29855
MYO1C 1.52E-06 rs4790152 0.386692 T C 0.5527 -0.0045 rs4790152 Hao_LUNG 0 G -8.3
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Fairfax_MONOCYTES-LPS24 6.05E-40 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Fairfax_MONOCYTES-LPS24 7.82E-35 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zeller_MONOCYTES 2.25E-28 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Westra_WHOLEBLOOD 3.24E-28 C -11.015
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Fairfax_MONOCYTES-LPS24 8.02E-15 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Westra_WHOLEBLOOD 6.52E-13 C -7.18937
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Raj_MONOCYTES 1.76E-12 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Raj_CD4TCELLS 4.44E-12 NA -9
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 LloydJones_WHOLEBLOOD 1.20E-11 C -0.199056
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Quach_MONOCYTES-baseline 1.93E-11 NA 0.4
NCF4 4.85E-08 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-gene-primary 1.85E-09 C -6.01071
NCF4 4.85E-08 rs5756391 8.53E-06 A G 0.3520 -0.0232 rs5756391 Westra_WHOLEBLOOD 3.81E-16 A 8.14455
NCF4 4.85E-08 rs4821549 0.0746725 A G 0.0646 -0.0182 rs4821549 Raj_CD4TCELLS 8.38E-29 NA -9
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Raj_CD4TCELLS 3.43E-70 NA -9
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Westra_WHOLEBLOOD 3.55E-36 A 12.5591
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Kasela_CD4TCELLS 1.34E-19 A 9.05737
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Fairfax_MONOCYTES-LPS24 2.13E-13 NA -9
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Fairfax_MONOCYTES-LPS24 2.29E-11 NA -9
NCF4 4.85E-08 rs2072710 0.329012 A G 0.2874 -0.0057 rs2072710 Westra_WHOLEBLOOD 1.11E-09 A -6.0922
NCF4 4.85E-08 rs5756363 0.353738 T G 0.1276 -0.0067 rs5756363 Westra_WHOLEBLOOD 3.61E-10 T -6.27023
NSMCE1 6.62E-07 rs4523932 5.15E-06 A G 0.0119 -0.1047 rs4523932 Nedelec_MACROPHAGES-listeria-asQTL 1.40E-22 NA 0.130657
NSMCE1 6.62E-07 rs4523932 5.15E-06 A G 0.0119 -0.1047 rs4523932 Nedelec_MACROPHAGES-baseline-asQTL 1.04E-17 NA -0.11553
NSMCE1 6.62E-07 rs9788909 0.00370886 A G 0.3452 0.0157 rs9788909 Zeller_MONOCYTES 1.72E-28 NA -9
NSMCE1 6.62E-07 rs9788909 0.00370886 A G 0.3452 0.0157 rs9788909 LloydJones_WHOLEBLOOD 2.00E-12 A 0.206931
NUP43 2.08E-06 rs6909158 7.46E-06 T C 0.8078 -0.0297 rs9478311 Westra_WHOLEBLOOD 8.60E-11 G -6.48984
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Hao_LUNG 0 T 8.36
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 LloydJones_WHOLEBLOOD 1.70E-149 C -0.738124
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Zhernakova_WHOLEBLOOD-gene-primary 1.88E-97 C -20.9498
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Fairfax_MONOCYTES-NAIVE 4.66E-74 NA -9
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Raj_CD4TCELLS 4.00E-53 NA -9
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 GTE_WHOLEBLOOD 8.91E-20 C -0.422135
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 LloydJones_WHOLEBLOOD 3.10E-15 C -0.223493
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Davenport_LEUCOCYTES 2.18E-14 NA -9
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Kim_MONOCYTES-LPS 9.04E-11 NA -9
NUP43 2.08E-06 rs4870139 1.29E-05 T C 0.6412 -0.0236 rs4870139 Kasela_CD8TCELLS 1.89E-10 C -6.37023
NUP43 2.08E-06 rs237004 0.000352558 A C 0.3316 0.0190 rs237004 Fairfax_MONOCYTES-LPS24 1.01E-11 NA -9













Table E4NUP43 2.08E-06 rs62439806 0.00671963 A G 0.0408 0.0371 rs62439806 LloydJones_WHOLEBLOOD 1.90E-10 A -0.545214
NUP43 2.08E-06 rs12523685 0.0240397 A T 0.7942 -0.0136 rs12523685 LloydJones_WHOLEBLOOD 1.20E-09 T -0.191625
NUP43 2.08E-06 rs2281436 0.0272181 T C 0.2874 0.0128 rs2281436 LloydJones_WHOLEBLOOD 3.60E-10 T -0.191296
NUP43 2.08E-06 rs9379347 0.102521 A G 0.0204 -0.0297 rs9379347 Raj_CD4TCELLS 8.84E-10 NA -9
NUP43 2.08E-06 rs78765468 0.117714 C G 0.0969 -0.0152 rs78765468 LloydJones_WHOLEBLOOD 9.20E-14 C 0.350226
NUP43 2.08E-06 rs112165893 0.16007 C G 0.9813 -0.0288 rs113263746 Raj_CD4TCELLS 2.49E-32 NA -9
NUP43 2.08E-06 rs112165893 0.16007 C G 0.9813 -0.0288 rs113263746 Raj_MONOCYTES 3.67E-26 NA -9
NUP43 2.08E-06 rs117067995 0.161872 A G 0.0510 -0.0181 rs117067995 Raj_MONOCYTES 3.61E-18 NA -9
NUP43 2.08E-06 rs117067995 0.161872 A G 0.0510 -0.0181 rs117067995 Raj_CD4TCELLS 1.95E-11 NA -9
NUP43 2.08E-06 rs13205080 0.186375 T C 0.0544 -0.0152 rs13205080 Raj_MONOCYTES 6.05E-13 NA -9
NUP43 2.08E-06 rs13205080 0.186375 T C 0.0544 -0.0152 rs13205080 Raj_CD4TCELLS 1.67E-10 NA -9
NUP43 2.08E-06 rs2151910 0.2168 A T 0.2500 -0.0074 rs2151910 Westra_WHOLEBLOOD 1.09E-41 A 13.5268
NUP43 2.08E-06 rs2151910 0.2168 A T 0.2500 -0.0074 rs2151910 LloydJones_WHOLEBLOOD 3.50E-28 A 0.341155
NUP43 2.08E-06 rs2151910 0.2168 A T 0.2500 -0.0074 rs2151910 Zhernakova_WHOLEBLOOD-gene-primary 9.44E-17 A 8.31178
NUP43 2.08E-06 rs7762285 0.266123 A G 0.8622 0.0092 rs7762285 Westra_WHOLEBLOOD 3.41E-15 G 7.87491
NUP43 2.08E-06 rs4870058 0.315372 A G 0.0544 -0.0145 rs4870058 Raj_CD4TCELLS 2.16E-29 NA -9
NUP43 2.08E-06 rs4870058 0.315372 A G 0.0544 -0.0145 rs4870058 LloydJones_WHOLEBLOOD 7.10E-16 A -0.534455
NUP43 2.08E-06 rs17733403 0.358474 A G 0.0646 -0.0093 rs17733403 Westra_WHOLEBLOOD 3.24E-10 A 6.28695
NUP43 2.08E-06 rs6922028 0.498364 T G 0.4626 0.0035 rs6922028 LloydJones_WHOLEBLOOD 3.20E-10 T 0.169703
NUP43 2.08E-06 rs60328093 0.546268 T C 0.0102 -0.0200 rs200592260 GTE_WHOLEBLOOD 7.31E-19 A -0.39905
NUP43 2.08E-06 rs60328093 0.546268 T C 0.0102 -0.0200 rs200592260 GTE_SKIN 2.75E-10 A -0.323661
NUP43 2.08E-06 rs9942443 0.590615 A C 0.2840 0.0031 rs9942443 LloydJones_WHOLEBLOOD 5.50E-13 A -0.222816
NUP43 2.08E-06 rs139394852 0.652985 A C 0.9235 -0.0051 rs139394852 Raj_CD4TCELLS 1.25E-16 NA -9
NUP43 2.08E-06 rs139394852 0.652985 A C 0.9235 -0.0051 rs139394852 Raj_MONOCYTES 5.90E-14 NA -9
NUP43 2.08E-06 rs2789503 0.681245 A G 0.4949 -0.0021 rs2789503 Westra_WHOLEBLOOD 3.28E-30 G -11.4212
NUP43 2.08E-06 rs2789503 0.681245 A G 0.4949 -0.0021 rs2789503 LloydJones_WHOLEBLOOD 5.60E-15 G -0.211463
NUP43 2.08E-06 rs2789503 0.681245 A G 0.4949 -0.0021 rs2789503 Fairfax_MONOCYTES-NAIVE 1.88E-10 NA -9
NUP43 2.08E-06 rs79782857 0.727052 A T 0.9864 -0.0070 rs79782857 Raj_CD4TCELLS 4.35E-13 NA -9
NUP43 2.08E-06 rs6918774 0.935752 T C 0.1327 -0.0007 rs6918774 LloydJones_WHOLEBLOOD 1.50E-11 T -0.288587
OR10J5 2.26E-06 rs2427837 1.02E-05 A G 0.2942 -0.0248 rs2427837 Westra_WHOLEBLOOD 6.38E-24 A 10.0858
OR10J5 2.26E-06 rs2494260 0.00142189 T C 0.2211 0.0186 rs2494260 Westra_WHOLEBLOOD 4.32E-13 T -7.24505
OR10J5 2.26E-06 rs6699459 0.00911848 A G 0.2058 -0.0160 rs6699459 Westra_WHOLEBLOOD 8.31E-17 A 8.32692
PRR5L 9.72E-07 rs7925585 2.78E-06 A G 0.6565 0.0244 rs7925585 Zhernakova_WHOLEBLOOD-gene-contextspecific 3.23E-12 G 6.96757
PRR5L 9.72E-07 rs7925585 2.78E-06 A G 0.6565 0.0244 rs7925585 Zhernakova_WHOLEBLOOD-exon-primary 2.35E-11 G 6.68226
PRR5L 9.72E-07 rs7925585 2.78E-06 A G 0.6565 0.0244 rs7925585 Zhernakova_WHOLEBLOOD-gene-primary 3.72E-11 G 6.6152
PRR5L 9.72E-07 rs12270539 0.000107622 T C 0.0374 0.0593 rs12270539 LloydJones_WHOLEBLOOD 2.90E-27 T -0.819609
PRR5L 9.72E-07 rs429034 0.117757 A T 0.7721 0.0099 rs429034 Zhernakova_WHOLEBLOOD-gene-primary 4.15E-19 T -8.93263
PRR5L 9.72E-07 rs429034 0.117757 A T 0.7721 0.0099 rs429034 Zhernakova_WHOLEBLOOD-exon-primary 4.02E-17 T -8.41232
PRR5L 9.72E-07 rs429034 0.117757 A T 0.7721 0.0099 rs429034 Zhernakova_WHOLEBLOOD-gene-contextspecific 3.41E-16 T -8.15788
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 1.96E-59 T 16.2581
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 3.01E-35 T -12.3886
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 3.03E-34 T -12.2021
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 1.99E-25 T -10.421
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-gene-primary 2.37E-21 T 9.4876
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 3.77E-19 T -8.94371
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exon-primary 1.48E-14 T 7.68951
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 1.88E-13 T -7.35723
PRR5L 9.72E-07 rs1123347 0.367446 T G 0.4303 0.0046 rs1123347 Zhernakova_WHOLEBLOOD-exonratio-primary 5.43E-11 T -6.55878
PRR5L 9.72E-07 rs12785381 0.492162 T C 0.0986 0.0061 rs12785381 Zhernakova_WHOLEBLOOD-exonratio-primary 1.06E-28 T -11.1153
PRR5L 9.72E-07 rs12785381 0.492162 T C 0.0986 0.0061 rs12785381 Zhernakova_WHOLEBLOOD-exon-primary 1.95E-27 T -10.8518
PRR5L 9.72E-07 rs10836545 0.82493 A G 0.9082 0.0021 rs10836545 Zhernakova_WHOLEBLOOD-exon-primary 5.84E-10 G 6.19496
PTPLA 8.16E-07 rs7092926 6.75E-07 T G 0.4320 0.0259 rs7092926 Zhernakova_WHOLEBLOOD-gene-primary 4.91E-12 T -6.90808
PTPLA 8.16E-07 rs7092926 6.75E-07 T G 0.4320 0.0259 rs7092926 Zhernakova_WHOLEBLOOD-gene-contextspecific 4.91E-12 T -6.90808
PTPLA 8.16E-07 rs17141430 0.0127591 A G 0.8759 -0.0203 rs17141430 Westra_WHOLEBLOOD 3.55E-10 G -6.27279
PTPLA 8.16E-07 rs78704091 0.0276797 A T 0.0680 -0.0184 rs78704091 Zhernakova_WHOLEBLOOD-gene-primary 1.05E-11 A 6.79888
PTPLA 8.16E-07 rs7094705 0.0361169 A G 0.3844 0.0111 rs7094705 Westra_WHOLEBLOOD 6.95E-23 A 9.84877













Table E4PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.61E-202 C -30.3645
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-gene-primary 1.61E-202 C -30.3645
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-exon-primary 9.85E-174 C -28.0997
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-exon-primary 1.58E-168 C -27.6705
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-exon-primary 3.02E-154 C -26.457
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zeller_MONOCYTES 9.09E-150 NA -9
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Battle_WHOLEBLOOD 7.06E-135 NA -9
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-exon-primary 6.01E-126 C -23.8717
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Fehrmann_WHOLEBLOOD 8.30E-100 G -21.21
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Jansen_WHOLEBLOOD 4.40E-93 C -0.436
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Walsh_WHOLEBLOOD 1.45E-28 T 0.810608
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 GTE_WHOLEBLOOD 2.20E-27 C -0.575968
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Battle_WHOLEBLOOD-ase 1.58E-21 NA -9
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-exonratio-primary 3.09E-18 C -8.70802
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Fehrmann_WHOLEBLOOD 2.10E-17 C -8.49
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Davenport_LEUCOCYTES 4.57E-15 NA -9
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Dinarzo_WHOLEBLOOD 1.07E-11 T 0.993866
PVALB 1.27E-07 rs4821544 3.58E-07 T C 0.6854 -0.0291 rs4821544 Zhernakova_WHOLEBLOOD-polyAratio-primary 2.07E-11 C -6.70078
PVALB 1.27E-07 rs1015775 0.000118906 A G 0.1769 -0.0263 rs1015775 LloydJones_WHOLEBLOOD 8.20E-69 A 0.625638
PVALB 1.27E-07 rs1015775 0.000118906 A G 0.1769 -0.0263 rs1015775 Zhernakova_WHOLEBLOOD-gene-primary 2.79E-44 A 13.9587
PVALB 1.27E-07 rs1015775 0.000118906 A G 0.1769 -0.0263 rs1015775 Walsh_WHOLEBLOOD 3.33E-14 A 0.711935
PVALB 1.27E-07 rs730483 0.0661628 A C 0.0816 0.0163 rs730483 LloydJones_WHOLEBLOOD 5.00E-19 A -0.397495
PVALB 1.27E-07 rs730483 0.0661628 A C 0.0816 0.0163 rs730483 Zhernakova_WHOLEBLOOD-gene-primary 1.72E-18 A -8.77384
PVALB 1.27E-07 rs74971025 0.0668636 A G 0.8435 -0.0135 rs74971025 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.37E-12 G -7.08692
PVALB 1.27E-07 rs74971025 0.0668636 A G 0.8435 -0.0135 rs74971025 LloydJones_WHOLEBLOOD 4.60E-11 G -0.258926
PVALB 1.27E-07 rs74971025 0.0668636 A G 0.8435 -0.0135 rs74971025 Zhernakova_WHOLEBLOOD-exon-primary 9.22E-11 G -6.47915
PVALB 1.27E-07 rs74971025 0.0668636 A G 0.8435 -0.0135 rs74971025 Zhernakova_WHOLEBLOOD-gene-primary 4.15E-10 G -6.24834
PVALB 1.27E-07 rs4820250 0.342696 A G 0.1344 -0.0068 rs4820250 Fairfax_MONOCYTES-LPS24 9.04E-15 NA -9
RBM15B 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-exon-primary 2.14E-52 A 15.233
RBM15B 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-gene-contextspecific 2.08E-44 A 13.9794
RBM15B 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-gene-primary 2.08E-44 A 13.9794
RBM15B 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Jansen_WHOLEBLOOD 8.50E-13 A 0.146
RP11-24N18.1 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-exon-primary 3.78E-22 A -9.67673
RP11-24N18.1 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-primary 1.27E-20 A -9.31092
RP11-24N18.1 1.71E-06 rs8056890 1.71E-06 A G 0.2959 -0.0254 rs8056890 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.27E-20 A -9.31092
RP11-264B17.4 1.05E-06 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 3.51E-130 C 24.276
RP11-264B17.4 1.05E-06 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-primary 4.38E-116 C 22.9027
RP11-264B17.4 1.05E-06 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-contextspecific 4.38E-116 C 22.9027
RP11-264B17.4 1.05E-06 rs67479058 0.000161762 T C 0.8503 -0.0258 rs67479058 Zhernakova_WHOLEBLOOD-gene-primary 2.55E-13 C -7.3162
RP11-264B17.4 1.05E-06 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Zhernakova_WHOLEBLOOD-gene-primary 2.51E-24 A -10.1769
RP11-534L20.5 1.32E-06 rs11117858 8.09E-06 T G 0.7840 -0.0287 rs11117858 Zhernakova_WHOLEBLOOD-gene-primary 4.88E-54 G -15.4778
RP11-534L20.5 1.32E-06 rs11117858 8.09E-06 T G 0.7840 -0.0287 rs11117858 Kasela_CD4TCELLS 7.94E-11 G -6.5018
RP11-534L20.5 1.32E-06 rs11117858 8.09E-06 T G 0.7840 -0.0287 rs11117858 Kasela_CD8TCELLS 1.12E-09 G -6.09141
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 Zhernakova_WHOLEBLOOD-gene-primary 5.77E-288 C 36.2652
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 Walsh_WHOLEBLOOD 1.69E-62 A -0.975764
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 Kasela_CD4TCELLS 3.09E-49 A -14.7498
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 Kasela_CD8TCELLS 2.55E-43 A -13.8
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 GTE_SKIN 1.09E-19 C 0.690688
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 GTE_WHOLEBLOOD 1.57E-17 C 0.600601
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 GTE_SKIN 7.58E-16 C 0.743489
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 GTE_FIBROBLASTS 1.21E-11 C 0.564444
RP11-534L20.5 1.32E-06 rs874718 5.06E-05 A C 0.4728 0.0211 rs874718 GTE_LUNG 7.63E-10 C 0.545556
RP11-534L20.5 1.32E-06 rs2987936 0.000433746 C G 0.5357 -0.0176 rs2987936 Zhernakova_WHOLEBLOOD-gene-primary 5.63E-70 G -17.6833
RP11-534L20.5 1.32E-06 rs2987936 0.000433746 C G 0.5357 -0.0176 rs2987936 Kasela_CD4TCELLS 5.97E-14 G -7.5086
RP11-534L20.5 1.32E-06 rs2987936 0.000433746 C G 0.5357 -0.0176 rs2987936 Kasela_CD8TCELLS 6.02E-12 G -6.87903
RP11-534L20.5 1.32E-06 rs2297546 0.00571061 C G 0.5901 -0.0158 rs2297546 Zhernakova_WHOLEBLOOD-gene-primary 1.52E-79 G -18.8846













Table E4RP11-534L20.5 1.32E-06 rs35785716 0.060621 T C 0.2517 -0.0113 rs35785716 Zhernakova_WHOLEBLOOD-gene-primary 6.88E-28 T 10.9469
RP11-534L20.5 1.32E-06 rs35785716 0.060621 T C 0.2517 -0.0113 rs35785716 Kasela_CD8TCELLS 2.13E-10 T 6.35156
RP11-534L20.5 1.32E-06 rs2336941 0.0952277 T C 0.1684 0.0109 rs2336941 Zhernakova_WHOLEBLOOD-gene-primary 2.35E-107 T -22.0092
RP11-534L20.5 1.32E-06 rs2336941 0.0952277 T C 0.1684 0.0109 rs2336941 Kasela_CD4TCELLS 1.45E-24 T -10.2303
RP11-534L20.5 1.32E-06 rs2336941 0.0952277 T C 0.1684 0.0109 rs2336941 Kasela_CD8TCELLS 2.63E-19 T -8.98323
RP11-534L20.5 1.32E-06 rs2336941 0.0952277 T C 0.1684 0.0109 rs2336941 Walsh_WHOLEBLOOD 1.23E-12 T -0.621843
RP11-534L20.5 1.32E-06 rs7538261 0.112295 A G 0.0629 0.0201 rs7538261 Zhernakova_WHOLEBLOOD-gene-primary 8.71E-17 A -8.32111
RP11-534L20.5 1.32E-06 rs74882519 0.374648 A G 0.0782 -0.0116 rs74882519 Zhernakova_WHOLEBLOOD-gene-primary 6.63E-51 A 15.0069
RP11-534L20.5 1.32E-06 rs6666087 0.376914 T C 0.5748 -0.0046 rs6666087 Zhernakova_WHOLEBLOOD-gene-primary 2.96E-12 C -6.97923
RP11-534L20.5 1.32E-06 rs61816859 0.415005 T C 0.0578 0.0109 rs61816859 Zhernakova_WHOLEBLOOD-gene-primary 1.36E-14 T -7.69955
RP11-534L20.5 1.32E-06 rs17433909 0.70506 T C 0.0612 0.0051 rs17433909 Zhernakova_WHOLEBLOOD-gene-primary 1.11E-12 T -7.11548
SPNS1 3.51E-09 rs2726040 4.84E-06 C G 0.5748 -0.0238 rs2726040 LloydJones_WHOLEBLOOD 5.10E-40 G -0.374583
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-primary 7.23E-258 C 34.3026
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-contextspecific 7.23E-258 C 34.3026
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 1.54E-237 C 32.9109
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 LloydJones_WHOLEBLOOD 9.20E-233 C 0.959846
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Battle_WHOLEBLOOD 9.62E-226 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Westra_WHOLEBLOOD 9.81E-198 C 50.796
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Fehrmann_WHOLEBLOOD 5.40E-177 G 28.37
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 8.15E-166 C 27.4443
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 6.31E-153 C 26.3424
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 7.74E-143 C 25.4465
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zeller_MONOCYTES 3.69E-133 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 3.51E-130 C 24.276
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-primary 4.38E-116 C 22.9027
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-contextspecific 4.38E-116 C 22.9027
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 5.38E-107 C 21.9716
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-exon-primary 3.90E-94 C 20.5831
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Fairfax_MONOCYTES-LPS24 1.23E-73 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Davenport_LEUCOCYTES 5.62E-30 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Grundberg_LCLS 2.72E-29 T -0.153062
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 GTE_WHOLEBLOOD 1.93E-24 T -0.284129
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Kim_MONOCYTES-LPS 2.25E-22 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Raj_MONOCYTES 2.62E-22 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.37E-21 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.91E-21 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 5.01E-21 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.50E-20 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 2.07E-20 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.41E-19 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Zhernakova_WHOLEBLOOD-gene-primary 4.73E-19 C 8.91852
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Kim_MONOCYTES-Baseline 8.22E-18 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.10E-16 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 6.93E-16 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.50E-14 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 GTE_LCLS 8.03E-14 T -0.841903
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 1.04E-13 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Geuvadis_LCLS 4.34E-13 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Raj_CD4TCELLS 3.76E-10 NA -9
SPNS1 3.51E-09 rs8045689 6.27E-06 T C 0.7466 0.0249 rs8045689 Dixon_LCLS 2.10E-09 C -0.508
SPNS1 3.51E-09 rs151230 2.06E-05 A G 0.1190 0.0326 rs151230 LloydJones_WHOLEBLOOD 1.00E-10 A -0.276115
SPNS1 3.51E-09 rs67479058 0.000161762 T C 0.8503 -0.0258 rs67479058 Zhernakova_WHOLEBLOOD-gene-primary 3.87E-21 C -9.43608
SPNS1 3.51E-09 rs67479058 0.000161762 T C 0.8503 -0.0258 rs67479058 LloydJones_WHOLEBLOOD 1.70E-18 C -0.323235
SPNS1 3.51E-09 rs67479058 0.000161762 T C 0.8503 -0.0258 rs67479058 Zhernakova_WHOLEBLOOD-gene-primary 2.55E-13 C -7.3162
SPNS1 3.51E-09 rs7201546 0.00291959 T C 0.1480 0.0240 rs7201546 Westra_WHOLEBLOOD 3.16E-16 T -8.16732
SPNS1 3.51E-09 rs7201546 0.00291959 T C 0.1480 0.0240 rs7201546 LloydJones_WHOLEBLOOD 7.10E-12 T -0.279907













Table E4SPNS1 3.51E-09 rs11643913 0.0032946 A G 0.0629 0.0519 rs11643913 LloydJones_WHOLEBLOOD 9.00E-14 A -0.551074
SPNS1 3.51E-09 rs11569775 0.146547 C G 0.9728 0.0206 rs11569775 LloydJones_WHOLEBLOOD 3.80E-22 G 0.71576
SPNS1 3.51E-09 rs7499778 0.193516 A G 0.5357 -0.0073 rs7499778 Zhernakova_WHOLEBLOOD-gene-primary 8.36E-22 G 9.59551
SPNS1 3.51E-09 rs7499778 0.193516 A G 0.5357 -0.0073 rs7499778 LloydJones_WHOLEBLOOD 1.50E-12 A -0.195003
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Westra_WHOLEBLOOD 4.65E-116 A -22.9
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 LloydJones_WHOLEBLOOD 1.10E-62 A -0.479659
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Zhernakova_WHOLEBLOOD-gene-primary 5.75E-60 A -16.3329
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Zeller_MONOCYTES 2.31E-27 NA -9
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Zhernakova_WHOLEBLOOD-gene-primary 2.51E-24 A -10.1769
SPNS1 3.51E-09 rs12448482 0.197731 A G 0.3861 0.0071 rs12448482 Grundberg_LCLS 2.76E-10 G 0.0862493
SPNS1 3.51E-09 rs139456978 0.461272 T C 0.0493 -0.0091 rs139456978 Zhernakova_WHOLEBLOOD-gene-primary 2.80E-19 T -8.97634
SPNS1 3.51E-09 rs75556002 0.675961 T C 0.0102 -0.0096 rs75556002 LloydJones_WHOLEBLOOD 1.30E-14 T 0.72673
SPNS1 3.51E-09 rs62035317 0.700585 A G 0.0663 0.0042 rs62035317 Zhernakova_WHOLEBLOOD-gene-primary 1.12E-11 A 6.79046
SPNS1 3.51E-09 rs7498329 0.797214 A C 0.7619 -0.0016 rs7498329 Westra_WHOLEBLOOD 1.53E-35 C -12.443
SPNS1 3.51E-09 rs7498329 0.797214 A C 0.7619 -0.0016 rs7498329 LloydJones_WHOLEBLOOD 4.60E-18 C -0.286571
SPNS1 3.51E-09 rs7498329 0.797214 A C 0.7619 -0.0016 rs7498329 Zhernakova_WHOLEBLOOD-gene-primary 2.26E-13 C -7.33211
SPNS1 3.51E-09 rs7498329 0.797214 A C 0.7619 -0.0016 rs7498329 Fehrmann_WHOLEBLOOD 3.10E-12 C -6.97
SPNS1 3.51E-09 rs8056259 0.894326 T C 0.2857 -0.0008 rs8056259 LloydJones_WHOLEBLOOD 2.50E-12 T 0.206418
SPNS1 3.51E-09 rs112918513 0.992411 A G 0.9099 -0.0001 rs112918513 Zhernakova_WHOLEBLOOD-gene-primary 7.39E-15 G 7.77772
SULT1A1 1.96E-07 rs75539558 1.57E-06 C G 0.6633 0.0250 rs75539558 Zhernakova_WHOLEBLOOD-exonratio-primary 3.89E-160 G 26.9642
SULT1A1 1.96E-07 rs75539558 1.57E-06 C G 0.6633 0.0250 rs75539558 Zhernakova_WHOLEBLOOD-gene-primary 2.32E-16 G -8.20409
SULT1A1 1.96E-07 rs75539558 1.57E-06 C G 0.6633 0.0250 rs75539558 GTE_WHOLEBLOOD 1.14E-12 G -0.355971
SULT1A1 1.96E-07 rs75539558 1.57E-06 C G 0.6633 0.0250 rs75539558 GTE_SKIN 1.06E-10 G -0.369911
SULT1A1 1.96E-07 rs231970 4.84E-06 A G 0.8827 -0.0350 rs231970 LloydJones_WHOLEBLOOD 8.30E-25 G -0.4597
SULT1A1 1.96E-07 rs231970 4.84E-06 A G 0.8827 -0.0350 rs231970 Zhernakova_WHOLEBLOOD-gene-primary 3.38E-16 G -8.15887
SULT1A1 1.96E-07 rs4788119 0.0205086 T G 0.8112 0.0149 rs4788119 LloydJones_WHOLEBLOOD 4.60E-18 G -0.288976
SULT1A1 1.96E-07 rs79476281 0.0875464 T C 0.0527 -0.0218 rs150089402 Zhernakova_WHOLEBLOOD-gene-contextspecific 6.54E-13 T -7.18876
SULT1A1 1.96E-07 rs79476281 0.0875464 T C 0.0527 -0.0218 rs150089402 Zhernakova_WHOLEBLOOD-exon-primary 7.26E-13 T -7.17432
SULT1A1 1.96E-07 rs79476281 0.0875464 T C 0.0527 -0.0218 rs150089402 Zhernakova_WHOLEBLOOD-exon-primary 9.51E-12 T -6.81362
SULT1A1 1.96E-07 rs4788115 0.122264 A T 0.2160 0.0112 rs4788115 LloydJones_WHOLEBLOOD 4.10E-12 A 0.242542
SULT1A1 1.96E-07 rs75227850 0.159471 T C 0.0238 -0.0191 rs75227850 LloydJones_WHOLEBLOOD 3.30E-16 T -0.610833
SULT1A1 1.96E-07 rs11540497 0.161972 A G 0.0493 -0.0197 rs11540497 LloydJones_WHOLEBLOOD 1.50E-10 A -0.390543
SULT1A1 1.96E-07 rs12935321 0.533018 A G 0.1224 0.0063 rs12445519 Zhernakova_WHOLEBLOOD-gene-primary 1.65E-29 G 11.2798
SULT1A1 1.96E-07 rs12935321 0.533018 A G 0.1224 0.0063 rs12445519 LloydJones_WHOLEBLOOD 1.20E-10 G 0.318144
TICAM2 1.67E-06 rs17137937 2.93E-06 T C 0.0748 0.0425 rs17137937 Hao_LUNG 0 C -8.88
TICAM2 1.67E-06 rs17137937 2.93E-06 T C 0.0748 0.0425 rs17137937 Westra_WHOLEBLOOD 3.67E-20 T 9.19745
TICAM2 1.67E-06 rs17137937 2.93E-06 T C 0.0748 0.0425 rs17137937 LloydJones_WHOLEBLOOD 5.70E-10 T 0.303195
TICAM2 1.67E-06 rs256938 0.00238245 A C 0.5646 0.0152 rs256938 Fairfax_MONOCYTES-NAIVE 2.06E-09 NA -9
TICAM2 1.67E-06 rs2546480 0.223513 T C 0.5527 -0.0061 rs2546480 Fairfax_MONOCYTES-IFN 3.12E-10 NA -9
TMEM236 1.92E-06 rs7092926 6.75E-07 T G 0.4320 0.0259 rs7092926 Zhernakova_WHOLEBLOOD-gene-primary 1.51E-26 T -10.6634
TMEM236 1.92E-06 rs7092926 6.75E-07 T G 0.4320 0.0259 rs7092926 Zhernakova_WHOLEBLOOD-gene-contextspecific 1.51E-26 T -10.6634
TMEM236 1.92E-06 rs7092926 6.75E-07 T G 0.4320 0.0259 rs7092926 Zhernakova_WHOLEBLOOD-exon-primary 4.45E-25 T -10.3442
TMEM236 1.92E-06 rs55999004 0.00597318 A T 0.1378 -0.0174 rs55999004 Zhernakova_WHOLEBLOOD-gene-primary 2.17E-10 A 6.34864
TMEM236 1.92E-06 rs45607131 0.0445172 T C 0.0697 0.0178 rs45607131 Zhernakova_WHOLEBLOOD-gene-primary 2.40E-11 T -6.67946
VPRBP 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-exon-primary 2.14E-52 A 15.233
VPRBP 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-gene-contextspecific 2.08E-44 A 13.9794
VPRBP 1.41E-07 rs73078636 1.41E-07 A G 0.1480 -0.0403 rs73078636 Zhernakova_WHOLEBLOOD-gene-primary 2.08E-44 A 13.9794














Table E5. Summary of the directional effect of the allergy-protective allele on gene expression, across all disease-associated eQTL of a given gene.
First author Tissue Decreased Increased Not available
ABO GTE LUNG 1 0 0 0 0
ABO GTE SKIN 1 0 0 0 0
ABO GTE WHOLEBLOOD 1 1 0 1 0
ABO Hao LUNG 2 0 0 0 0
ABO Yao WHOLEBLOOD 1 1 0 1 0
ABO Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
ABO Zhernakova WHOLEBLOOD-exonratio-primary 1 1 0 1 0
ABO Zhernakova WHOLEBLOOD-gene-contextspecific 2 1 0 1 0
ABO Zhernakova WHOLEBLOOD-gene-primary 12 5 0 5 0
AC004893.11 Zhernakova WHOLEBLOOD-exon-primary 1 1 1 0 0
AC004893.11 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 1 0 0
AC004893.11 Zhernakova WHOLEBLOOD-gene-primary 1 1 1 0 0
APOBR LloydJones WHOLEBLOOD 1 1 0 1 0
APOBR Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
APOBR Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
APOBR Zhernakova WHOLEBLOOD-gene-primary 1 1 0 1 0
ATXN2L Zhernakova WHOLEBLOOD-exon-primary 1 1 1 0 0
ATXN2L Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 1 0 0
ATXN2L Zhernakova WHOLEBLOOD-gene-primary 1 1 1 0 0
FOSL2 Walsh WHOLEBLOOD 1 1 0 1 0
FOSL2 Zhernakova WHOLEBLOOD-exonratio-primary 1 1 0 1 0
IL27 Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
IL27 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
IL27 Zhernakova WHOLEBLOOD-gene-primary 2 2 0 2 0
IPCEF1 Battle WHOLEBLOOD 1 1 0 0 1
IPCEF1 GTE SKIN 1 0 0 0 0
IPCEF1 Zhernakova WHOLEBLOOD-exon-primary 2 2 1 1 0
IPCEF1 Zhernakova WHOLEBLOOD-exonratio-primary 1 1 1 0 0
IPCEF1 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
IPCEF1 Zhernakova WHOLEBLOOD-gene-primary 2 2 0 2 0
LAT Fehrmann WHOLEBLOOD 2 2 0 1 1
LAT Zhernakova WHOLEBLOOD-exon-primary 1 0 0 0 0
LAT Zhernakova WHOLEBLOOD-gene-primary 2 1 0 1 0
20 genes with replication gene-based P<0.0016
Gene
eQTL study N eQTL 
tested
N eQTL with P<0.05 in adjusted allergic disease GWAS
Total













NCF4 Fairfax MONOCYTES-LPS24 2 1 0 0 1
NCF4 Kasela CD4TCELLS 1 0 0 0 0
NCF4 LloydJones WHOLEBLOOD 1 1 0 1 0
NCF4 Quach MONOCYTES-baseline 1 1 0 0 1
NCF4 Raj CD4TCELLS 3 1 0 0 1
NCF4 Raj MONOCYTES 1 1 0 0 1
NCF4 Westra WHOLEBLOOD 4 2 0 2 0
NCF4 Zeller MONOCYTES 1 1 0 0 1
NCF4 Zhernakova WHOLEBLOOD-gene-primary 1 1 0 1 0
NSMCE1 LloydJones WHOLEBLOOD 1 1 1 0 0
NSMCE1 Nedelec MACROPHAGES-baseline-asQTL 1 1 0 0 1
NSMCE1 Nedelec MACROPHAGES-listeria-asQTL 1 1 0 0 1
NSMCE1 Zeller MONOCYTES 1 1 0 0 1
OR10J5 Westra WHOLEBLOOD 3 3 0 3 0
PRR5L LloydJones WHOLEBLOOD 1 1 0 1 0
PRR5L Zhernakova WHOLEBLOOD-exon-primary 5 1 0 1 0
PRR5L Zhernakova WHOLEBLOOD-exonratio-primary 2 0 0 0 0
PRR5L Zhernakova WHOLEBLOOD-gene-contextspecific 2 1 0 1 0
PRR5L Zhernakova WHOLEBLOOD-gene-primary 3 1 0 1 0
PVALB Battle WHOLEBLOOD 1 1 0 0 1
PVALB Battle WHOLEBLOOD-ase 1 1 0 0 1
PVALB Davenport LEUCOCYTES 1 1 0 0 1
PVALB Dinarzo WHOLEBLOOD 1 1 0 1 0
PVALB Fairfax MONOCYTES-LPS24 1 0 0 0 0
PVALB Fehrmann WHOLEBLOOD 1 1 0 1 0
PVALB GTE WHOLEBLOOD 1 1 0 1 0
PVALB Jansen WHOLEBLOOD 1 1 0 1 0
PVALB LloydJones WHOLEBLOOD 4 2 0 2 0
PVALB Walsh WHOLEBLOOD 2 2 0 2 0
PVALB Zeller MONOCYTES 1 1 0 0 1
PVALB Zhernakova WHOLEBLOOD-exon-primary 2 1 0 1 0
PVALB Zhernakova WHOLEBLOOD-exonratio-primary 1 1 0 1 0
PVALB Zhernakova WHOLEBLOOD-gene-contextspecific 2 1 0 1 0
PVALB Zhernakova WHOLEBLOOD-gene-primary 4 2 0 2 0
PVALB Zhernakova WHOLEBLOOD-polyAratio-primary 1 1 0 1 0
RBM15B Jansen WHOLEBLOOD 1 1 0 1 0
RBM15B Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
RBM15B Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0













RP11-24N18.1 Zhernakova WHOLEBLOOD-exon-primary 1 1 1 0 0
RP11-24N18.1 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 1 0 0
RP11-24N18.1 Zhernakova WHOLEBLOOD-gene-primary 1 1 1 0 0
RP11-264B17.4 Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
RP11-264B17.4 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
RP11-264B17.4 Zhernakova WHOLEBLOOD-gene-primary 3 2 0 2 0
RP11-534L20.5 GTE FIBROBLASTS 1 1 0 1 0
RP11-534L20.5 GTE LUNG 1 1 0 1 0
RP11-534L20.5 GTE SKIN 1 1 0 1 0
RP11-534L20.5 GTE WHOLEBLOOD 1 1 0 1 0
RP11-534L20.5 Kasela CD4TCELLS 4 3 0 3 0
RP11-534L20.5 Kasela CD8TCELLS 5 3 0 3 0
RP11-534L20.5 Walsh WHOLEBLOOD 2 1 0 1 0
RP11-534L20.5 Zhernakova WHOLEBLOOD-gene-primary 12 5 0 5 0
SPNS1 Battle WHOLEBLOOD 1 1 0 0 1
SPNS1 Davenport LEUCOCYTES 1 1 0 0 1
SPNS1 Dixon LCLS 1 1 1 0 0
SPNS1 Fairfax MONOCYTES-LPS24 1 1 0 0 1
SPNS1 Fehrmann WHOLEBLOOD 2 1 0 0 1
SPNS1 Geuvadis LCLS 1 1 0 0 1
SPNS1 Grundberg LCLS 2 1 0 1 0
SPNS1 GTE LCLS 1 1 0 1 0
SPNS1 GTE WHOLEBLOOD 1 1 0 1 0
SPNS1 Kim MONOCYTES-Baseline 1 1 0 0 1
SPNS1 Kim MONOCYTES-LPS 1 1 0 0 1
SPNS1 LloydJones WHOLEBLOOD 12 6 0 6 0
SPNS1 Raj CD4TCELLS 1 1 0 0 1
SPNS1 Raj MONOCYTES 1 1 0 0 1
SPNS1 Westra WHOLEBLOOD 4 2 0 2 0
SPNS1 Zeller MONOCYTES 2 1 0 0 1
SPNS1 Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
SPNS1 Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
SPNS1 Zhernakova WHOLEBLOOD-gene-primary 9 3 0 3 0
SULT1A1 GTE SKIN 1 1 1 0 0
SULT1A1 GTE WHOLEBLOOD 1 1 1 0 0
SULT1A1 LloydJones WHOLEBLOOD 6 2 1 1 0
SULT1A1 Zhernakova WHOLEBLOOD-exon-primary 1 0 0 0 0
SULT1A1 Zhernakova WHOLEBLOOD-exonratio-primary 1 1 0 1 0













SULT1A1 Zhernakova WHOLEBLOOD-gene-primary 3 2 1 1 0
VPRBP Zhernakova WHOLEBLOOD-exon-primary 1 1 0 1 0
VPRBP Zhernakova WHOLEBLOOD-gene-contextspecific 1 1 0 1 0
VPRBP Zhernakova WHOLEBLOOD-gene-primary 1 1 0 1 0
CASZ1 Kim MONOCYTES-Baseline 1 1 0 0 1
CASZ1 Kim MONOCYTES-LPS 1 1 0 0 1
CASZ1 LloydJones WHOLEBLOOD 1 0 0 0 0
CASZ1 Zhernakova WHOLEBLOOD-exonratio-primary 1 0 0 0 0
FPR1 Battle WHOLEBLOOD-ase 1 0 0 0 0
FPR1 GTE FIBROBLASTS 1 0 0 0 0
FPR1 GTE WHOLEBLOOD 1 1 0 1 0
FPR1 Hao LUNG 1 1 0 1 0
FPR1 LloydJones WHOLEBLOOD 7 3 0 3 0
FPR1 Walsh WHOLEBLOOD 2 1 0 1 0
FPR1 Westra WHOLEBLOOD 6 3 0 3 0
FPR1 Zeller MONOCYTES 1 1 0 0 1
FPR1 Zhernakova WHOLEBLOOD-exon-primary 3 1 0 1 0
FPR1 Zhernakova WHOLEBLOOD-exonratio-primary 1 0 0 0 0
FPR1 Zhernakova WHOLEBLOOD-gene-primary 7 6 0 6 0
TICAM2 Fairfax MONOCYTES-IFN 1 0 0 0 0
TICAM2 Fairfax MONOCYTES-NAIVE 1 1 0 0 1
TICAM2 Hao LUNG 1 1 1 0 0
TICAM2 LloydJones WHOLEBLOOD 1 1 1 0 0
TICAM2 Westra WHOLEBLOOD 1 1 1 0 0













Gene Chr BP (start) (1) Asthma vs Hay fever (2) Asthma vs Eczema (3) Hay fever vs Eczema
OR10J5 1 159504793 0.0074 0.6664 0.3608
RP11-534L20.5 1 206677281 0.5574 0.2689 0.6935
FOSL2 2 28615315 0.2191 0.1755 0.1056
RBM15B 3 51428731 0.3264 0.9377 0.1260
VPRBP 3 51433298 0.3264 0.9377 0.1260
IPCEF1 6 154475631 0.2120 0.8854 0.6763
AC004893.11 7 98610788 0.9747 0.8107 0.8938
ABO 9 136125788 0.6017 0.2920 0.7406
PRR5L 11 36317838 0.0911 0.3894 0.8578
NSMCE1 16 27236312 0.6497 0.7415 0.2882
APOBR 16 28505970 0.2789 0.9077 0.4636
IL27 16 28510683 0.4716 0.9111 0.3380
SULT1A1 16 28616903 0.1836 0.9831 0.3116
ATXN2L 16 28834356 0.2188 0.9266 0.1121
RP11-24N18.1 16 28841933 0.2188 0.9266 0.1121
SPNS1 16 28985542 0.4876 0.5549 0.2796
RP11-264B17.4 16 28986294 0.5000 0.3676 0.0202
LAT 16 28996147 0.3288 0.5084 0.0163
PVALB 22 37196728 0.4415 0.2531 0.3182
NCF4 22 37257030 0.8812 0.8216 0.6894
Table E6. Results (i.e. EUGENE P-value) from gene-based association analyses of three case-only 
phenotypes comparing three non-overlapping groups of adults: (1) asthma only cases (n=12,268) versus hay 
fever only cases (n=33,305); (2) asthma only cases (n=12,268) versus eczema only cases (n=6,276); and (3) 
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Rationale for performing the conditional analysis prior to the gene-based analysis 
The goal of our gene-based analysis was to identify genes with a significant association with allergic 
disease risk that was not driven by the 136 sentinel allergy risk SNPs reported by Ferreira et al. 1. In 
practice, applying the gene-based test to the original results of Ferreira et al. 1 (i.e. before conditional 
analysis) would not be the best way to achieve that goal. Had we done so, there would be hundreds 
(exactly 362) of genes with a significant association at the genome-wide significance threshold of 
P<2.5x10-6 (Figure E2). Most of the 362 genes are located in close proximity to (<1 Mb) the 136 
sentinel allergy risk SNPs that we reported by Ferreira et al. 1, and so the observed gene-based 
associations are very likely to be driven by those known allergy risk SNPs. As indicated above, the goal 
of our analysis was not to identify such genes, but instead those with a gene-based association driven 
by potentially new allergy risk SNPs. 
 
To do so, we could have simply filtered out genes that were located “close” to the 136 sentinel risk 
SNPs reported by Ferreira et al. 1. But that is not an ideal approach, because LD patterns are not 
uniform throughout the genome, with substantial LD between variants found at distances of >1 Mb in 
some regions 2. So if we had defined “close” as <1 Mb from a sentinel variant, then we could 
potentially fail to filter out genes located at a greater distance but still with an association driven by a 
known allergy risk SNP. Conversely, had we used a distance threshold that would ensure linkage 
equilibrium across the genome between the Ferreira et al. 1 sentinel risk SNPs and eQTL (e.g. >10 Mb), 
we would potentially encounter the opposite problem, and filter out genes with an association not 
driven by a known allergy risk SNP. 
 
Another approach could have been to remove results for the 136 sentinel risk SNPs (and for any other 















exclusions. In our view, this is more appropriate than the “distance-based” approach described above, 
but still not ideal, because it requires defining a threshold to identify variants in LD with the sentinel 
risk SNPs. Should this be an r2 of 0.10, 0.05, or 0.01? The threshold selected could in practice turn out 
to be too liberal or too conservative. 
 
Instead of the distance- or LD-based filtering approaches described above, we argue that a more 
efficient (and still simple and robust) approach to identify genes with an association not driven by a 
sentinel risk SNP identified in Ferreira et al. 1, is to first adjust the single-SNP results of that GWAS for 
the effects of the sentinel risk SNPs identified in that GWAS. Then apply the gene-based test to the 
adjusted GWAS results. Approximate conditional association analysis can be (and was in our study) 
performed with the GCTA tool 2, requiring only summary statistics from the GWAS and genotype data 
from individuals with an ancestry that is representative of the studies that were included in the GWAS 
(we used 5,000 Europeans from the UK Biobank). 
 
In practice, the P-value for any variant located >10 Mb from a sentinel risk SNP is the same before and 
after the conditional analysis performed with GCTA, because both variants are considered to be in 
linkage equilibrium. For variants located <10 Mb from a sentinel variant, the P-value after the 
conditional analysis in GCTA will be attenuated if in (and in proportion to the) LD with the nearby 
sentinel risk SNP(s). At one extreme (when r2=0), the P-value will be (almost if not) identical before 
and after conditional analysis. On the other hand, if the r2 between the test variant and the sentinel 
variant is 1, then the P-value after conditioning on the sentinel variant will be 1 (or very close to). 
 
When we applied the gene-based test to the adjusted GWAS results, we identified 30 genes with a 















(i.e. prior to the conditional analysis) was virtually unchanged (see Figure E2), confirming that the 
conditional analysis had not introduced biases that affected our results.  
 
Regarding the observed inflation of test statistics after the conditional analysis (lambda of 1.17), it is 
important to note that lambda was greater (1.19) in our original GWAS1 (i.e. prior to the conditional 
analysis). Therefore, the conditional analysis did not cause a systematic inflation of test statistics. We 
showed in Ferreira et al. 1 that most of this inflation is likely to reflect the polygenic nature of allergic 
disease risk and the large sample size used, which results in many thousands of SNPs being truly 
associated with disease risk (which increases lambda). This is likely to be the case because the inflation 
due to technical biases was only 1.04 (intercept from LD score regression analysis 2). The Ferreira et al. 
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Figure E1. Distribution of the observed and expected single-SNP association P-values obtained after 
adjusting the results from Ferreira et al. 1 (which included a correction for an inflation factor of 1.04; 
see Methods for details) for the effects of the 136 independent associations identified in that study. The 
genomic inflation factor (λ, estimated as the median chi-square divided by 0.4549) of the single-SNP 
results after the conditional analysis is also shown (λ = 1.17); before the conditional analysis, λ was 
1.19. The intercept of LD-score regression was 1.00, both before and after the conditional analysis. 
 
Figure E2. Comparison of results from the EUGENE gene-based test obtained before (x-axis) and after 
(y-axis) adjusting the Ferreira et al.1 GWAS results for the effects of the sentinel risk SNPs identified in 
that GWAS. The vertical and horizontal blue lines indicate the P-value threshold used to identify 
significant associations after accounting for multiple testing (P=2.5x10-6). 
